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Recent research has revealed that cells dynamically sense and respond to their 
physical microenvironments. In hematology, it has been shown that shear mediated red 
blood cell (RBC) deformation results in release, and that platelets attenuate contraction 
force based on substrate stiffness. Blood cells exist in a dynamic fluidic microenvironment, 
and they also interact with various matrices such as fibrin clots and the extracellular matrix 
proteins. The objective of this thesis is thus to create microfluidic systems in which the 
biophysical and biochemical aspects of hematological processes are independently 
investigated toward the aim of discovering new solution spaces for diagnostics and 
therapeutics. To that end, this work presents novel microfluidic systems: 1) an 
“endothelial”-ized, T-junction fluidic to elucidate the biophysical processes that define the 
mechanism of action of the ferric chloride thrombosis model and 2) microfluidic devices 
with single-micron features (pillars and canals) to examine the effects of physical 
interactions between blood cells—RBCs, platelets, and neutrophils—and geometrically 
relevant, non-biological matrices at the single cell level.  
Using the T-junction fluidic I resolved the mechanism of action of the most 
commonly used thrombosis injury model – the ferric chloride- thrombosis model. I show 
that the mechanism of action of ferric chloride is non-biological in nature. Rather, the 
chemical induces charge-based aggregation of blood cells that then triggers the 
conventional clotting cascade. This finding both reconciles discrepancies in the literature, 
and cautions researchers against using this injury model, especially for the study of clot 
initiation. My work also highlights the importance of considering mass transfer properties 
in biological processes.  
 xv
The second suite of devices recapitulates the physical dimensions of vascular 
matrices with which blood cells interact. By combining electron beam lithography, 
photolithography, and soft lithography, I considered hematological questions that were 
previously technologically infeasible. I found that the physical presence of a micropillar 
array creates a shear microgradient that leads to the localized adherence and aggregation 
of platelets that propagates to stem blood flow in the absence of exogenous agonists. 
Furthermore, I visualized the process of RBC fragmentation (schistocyte formation) real-
time in an in vitro system by creating microcanals that force RBCs to deform through a 
small cross-sectional area over various distances. This suggests that RBC fragmentation is 
a time dependent process, contrary to what is historically cited in medical literature. 
Furthermore, pathologically altered cells—RBCs from a patient with SCD—have an 
altered fragmentation profile as compared to healthy cells. Finally, by perfusing neutrophils 
through the microcanals, I show that mechanical forces can cause neutrophils to fragment 
into membranous debris that has neutrophil extracellular trap (NET)-like properties. These 
NET-like surfaces appear to be procoagulant in that they bind platelets and display histone, 
elastase and MPO. This suggests new insight into the pathological role of neutrophils in 
thrombosis. Moreover, RBCs become trapped in the neutrophil membrane, and can 
hemolyze as a result. This system them provides insights into the synergy between 
hemolytic anemias, sepsis, and thrombosis. Microfluidic platforms allow for real-time, 
microscopic evaluation of cell response (via both brightfield morphology analysis and 
immunostaining) and precise spatiotemporal control of system inputs and flow 
characteristics, including shear stress. The mechanistic understandings gained by creating 
systems that successfully decouple the biophysical and biological aspects of blood cells, as 
 xvi
is done in this work, can result in enhanced understanding of the etiology of pathologies, 








CHAPTER 1: INTRODUCTION 
In vivo animal models and in vitro biological assays continue to be indispensable to the 
study of hematology. However, as recent research reveals that cells dynamically sense and 
respond to their physical microenvironments, assays that decouple biophysical and 
biological processes have become increasingly important. Blood cells pass through, and 
interact with, biological matrices such as fibrin clots and endothelial cell gaps, but the 
physical and biochemical aspects of these interactions are relatively indistinguishable from 
one another in vivo. A more global understanding of the effects of biophysical factors—
e.g. mass transfer, pressure, and physical dimensions– on hematological processes will 
inform the field towards a new set of solutions.  
1.1  Motivation 
Numerous cellular mechanics studies have shown that cells dynamically sense and 
respond to physical signals in their microenvironments.1, 2 As blood cells exist in a 
biological environment that is governed by fluid mechanics, their response to biophysical 
stimuli is of great interest. Hemostasis, or the cessation of blood flow, is a tenuous system 
made up of feedback loops that ensure that clotting stops blood loss, but does not impede 
blood flow; therefore, both the inability to clot and pathological clotting (thrombosis) form 
a significant body of research in hematology. Cardiovascular disease is the leading cause 
of death globally, and thrombosis is the underlying pathology in conditions such as heart 
attack and stroke. Further, thrombosis resulting from medical implants presents a new 
avenue for research considerations. Clotting is known to be regulated by physical processes 
in a number of ways: mass transfer of clotting agonists from the injury site, elevated shear 
causing platelet activation and aggregation, disturbed flow causing endothelial cell 
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dysfunction, etcetera. 3 Physical alterations in the fluidic environment, such as in stenotic 
vessels or implanted heart valves, then greatly affects hemostasis and pathological clotting. 
Having a better understanding of the effects of physical parameters on blood cells gives a 
more global understanding of hematology and thus presents a previously unconsidered 
realm of solutions for blood cell activity assays and antithrombotic therapeutics. 
 
1.2  Research Objectives and Specific Aims 
The long term goal of the project is to enhance understanding of the biophysical 
aspects of hematological processes to improve diagnostic assays and to inspire the 
discovery of novel therapeutic targets. The overall objective of this work is to develop 
microfluidic systems in which precise spatiotemporal control of experimental conditions 
allows for biological and biophysical effects to be considered independently, towards the 
aim of resolving unknown mechanisms in hematology. My central hypothesis is that 
microfluidics can be leveraged to study hematological processes in a reductionist manner, 
where confounding biological and biophysical factors are considered both in isolation and 
in conjunction, with the aim of resolving longstanding questions in hematology. My central 
hypothesis will be tested in the following specific aims: 
 
Aim 1. Resolve the mechanism of the ferric chloride (FeCl3) injury model.  A T-junction 
microfluidic was designed to recapitulate the introduction of FeCl3 to a blood vessel lumen. 
By introducing FeCl3 to blood components and endothelial cells in a reductionist manner, 
I could resolve the mechanism of injury in the FeCl3-induced thrombosis model. Flow into 
each channel can be controlled by a syringe pump to create an interface of the two fluid 
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streams near the wall of the main channel (as it would in the luminal introduction of a 
chemical in vivo) for the real-time monitoring of blood cell aggregation. Individual blood 
cells can thus be exposed to FeCl3, in the presence and absence of endothelial cells, to 
explore the many interrelated facets of the in vivo experimental space. Furthermore, the in 
vitro model can assess the effects of FeCl3 in altered clotting environments (in the presence 
of therapeutics and in clotting deficient blood), to have a more global understanding of the 
injury mechanism. Finally, by characterizing the role of mass transfer in this model, the 
experimental differences related to the concentration of FeCl3 and the vessel it is applied 
to can be elucidated. Chapter 3 describes this work and concludes with a description of the 
mechanism of the injury model. 
 
Aim 2. Create a suite of devices to probe the interaction of blood cells with their physical 
microenvironment. The working hypothesis was that a combination of microfabrication 
techniques could be leveraged to create microfluidic devices that allow for the 
recapitulation of interactions between single blood cells and their physical 
microenvironments.  The interaction of cells with these physical structures could then be 
monitored real time via microscopy to have a better understanding of biophysical stimulus 
on blood cells. Electron beam lithography (EBL), in combination with photolithography 
and soft lithography, can be used to create microfluidic devices with robust, repeatable, 
single micron features. To that end, I created an array of micropillars that recapitulates the 
gaps and fibers that a platelet would traverse and interact with, to establish the effect of a 
physical matrix on platelet activation and aggregation. The interaction of the biophysical 
and biochemical can be probed by adsorbing biologics to the micropillar surfaces. For the 
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second half of this aim, I designed and fabricated a microcanal device that challenges RBCs 
to deform through a 2x3 µm cross-section over various distances. RBCs are monitored real 
time to gain insight into the parameter space for RBC fragmentation. Blood from a patient 
with SCD was perfused through the microcanal array to determine how pathological 
changes in RBCs change their fragmentation profile. Finally, neutrophils can be perfused 
through the microcanal array to monitor their interaction with the physical barrier. 
Neutrophils, red blood cells, and platelets can then be perfused through the microcanal 
device to better understand how the cells interact with one another as well as with the 
physical matrix. The experimental procedures and results of these studies are described in 
Chapter 4.  
  
1.3  Significance of Results 
The results of this work have significant impacts for the field of hematology.  The 
successful completion of the first aim—to resolve the mechanism of action of the FeCl3 
injury model—both resolves discrepancies between previous literature findings in the field 
and cautions researchers on the use of the injury model in future research. By showing that 
the initiation of clotting in this model is non-biological in nature, I suggest that the model 
not be used to describe the biological receptor-ligand interactions of clot initiation. Further, 
results must be interpreted cautiously when using this model as there are likely significant, 
unknowable experimental artifacts. I also found that the extent of thrombosis in this model 
was directly related to mass transfer of FeCl3 in the vessel, thus providing insight into 
differences reported in the literature for thrombosis in different vessel types (that vary in 
diameter and blood velocity, and thus mass transfer parameters). 
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The work completed in the second aim serves to begin to decouple the biophysical 
cues of vascular matrices from the biochemical. This is especially important when 
considering the widespread clotting that occurs in a number of disparate disease states, 
from sickle cell disease to sepsis. By creating a suite of devices that have single-micron 
scale features, I have created enabling technology that allows for the real-time monitoring 
of interactions between blood cells and their physical microenvironment. I show that the 
physical microenvironment, in and of itself, is able to regulate platelet activity. Further, 
that red blood cell fragmentation is a force and time dependent process, and that 
schistocytes and red blood cell derived microparticles can be created through a purely 
mechanical process.   Finally, I show that the mechanical disruption of a neutrophil under 
flow results in “NET-like” membranous material whose backbone is DNA and that is 
studded with histone, elastase, and MPO.  When the components are considered together, 
I find that mechanically induced NET-like material is procoagulant and entraps RBCs, as 
is seen in NETs implicated in thrombosis in vivo. Overall my findings suggest a role for 
cellular mechanics at the interface of inflammation and clotting, and informs how cell types 
respond in concert to biophysical challenges. This novel result is both pathophysiologically 






CHAPTER 2: BACKGROUND  
2.1  Hemostasis 
2.1.1 Blood Components 
Blood is a colloidal suspension of cells in a protein-rich aqueous solution. Broadly, 
red blood cells (5 billion cells/ mL of blood) are anuclear cells whose chief role is in oxygen 
transport throughout the body. White blood cells (5 million/ mL) are primarily involved in 
the immune response, with the greatest subset—granulocytes—being the noted first-
responder of the innate immune system. Platelets (500 million / mL) are fragments of 
megakaryocytes that form the main cellular component of clots. Blood proteins play 
various physiological roles ranging from the transport of nutrients and hormones to the 
regulation of clotting and the activation of the immune system. Of particular importance to 
clotting are fibrinogen, the fibrous component of clots, and coagulation factors, which 
circulate in a quiescent state. Blood cells and proteins play an interconnected role in 
physiologic and pathologic processes, the extent and details of which are still being 
discovered. 
2.1.2 Clotting Cascade  
Integral to the study of hematology is an understanding of hemostasis, or the cessation 
of blood flow. There is a tenuous balance between insufficient clotting and excessive 
clotting (thrombosis) that must be maintained for physiological function. To this end there 
are tightly controlled positive and negative feedback loops to provide a rapid, localized 
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response to blood vessel damage. The coagulation cascade describes the positive feedback 
loop, and is an extraordinarily complex series of reactions that converts coagulation factors 
to their active states; it is typically divided into two pathways: contact activation (extrinsic) 
and tissue factor (intrinsic). These pathways converge in a common pathway whereby 
thrombin is produced, which then converts fibrinogen to its polymerized form, fibrin. 
Fibrin binds platelets that have bound to the injury site and those in flow, and the combined 
platelets and fibrin form a hemostatic plug. Platelets gradually contract, expelling liquid 
and allowing the fibrin/ platelet clot to effectively seal off the injury while minimally 
obstructing blood flow. It should be noted that the distinction between the contact and 
tissue factor pathways is one made in controlled in vitro experiments; in reality, both 
processes likely occur in tandem in vivo. 
Briefly, the contact pathway describes the process by which factors are activated when 
interacting with a negatively charged surface. This surface can be a foreign body (e.g., 
glass) or the activated surface of a platelet or white blood cell. Deficiencies in the contact 
pathway seem to have consequences for thrombosis, but not explicitly for hemostasis. The 
tissue factor pathway is more integral to hemostasis (Figure 2.1); a deficiency in this 
pathway’s coagulation factors leads to a bleeding disorder (e.g., factors VII and VIII in 
hemophilia). Briefly, the tissue factor pathway describes the process by which exposure of 
the subendothelium leads to release of tissue factor. Tissue factor then activates coagulation 
factors.  As stated, both pathways result in the crosslinking of fibrinogen into insoluble 
fibrin that forms the fibrous, mesh component of clots.  
Platelets play an integral role in the initiation, propagation, and resolution of clotting. 
In addition to the tissue factor produced during endothelial injury, the injury physically 
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exposes the subendothelial matrix, namely collagen and fibronectin, to which platelets bind 
via transmembrane proteins called integrins. Platelet arrest and activation leads to their 
release of soluble agonists, which further recruits and activates platelets.4  Platelets can 
also be activated by thrombin and elevated shear stress. When platelets are activated, the 
usually internal phospholipid, phosphatidylserine, moves to the outer surface and creates a 
local procoagulant surface. In arteries where fluid forces are of a certain magnitude, von 
Willebrand Factor (vWF) also plays a role in platelet arrest and clot propagation.  
 
Figure 2.1. The haemostatic response to injury.  When the endothelium is disrupted by 
injury, tissue factor (which is not present on platelets, or on endothelial cells under normal 
physiological conditions) is exposed to factor VIIa to initiate the complex series of 
reactions… which give rise to fibrin. The fibrin monomer, which is composed of three 
different proteins, undergoes polymerization and binds with platelets to the 
subendothelium to form a haemostatic plug, called the thrombus. Platelets normally 
circulate in a resting form but are activated at the site of injury, releasing many different 
chemicals from granules inside the cell (indicated here as grains in the circulating platelets) 
which are important to platelet adhesion, aggregation and coagulation. Taken from [5]. 
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While RBCs do not play an immediate known biochemical role in the coagulation 
process, due to their significant numbers in circulation, they become trapped in fibrin clots 
and interact extensively with clots, especially in the microcirculation (Figure 2.2). 
Likewise, white blood cells have been shown to interact with platelets and contribute to 
the tissue factor branch of the coagulation cascade.  
 
 
Figure 2.2 SEM of blood clot. Fibrin (green) and platelets (purple) form the structural 
meshwork of the clot, while red blood cells (red) and white blood cells are trapped in the 
meshwork. Image Microfluidics  
While in vivo animal models allow for the systemic study of biological processes, the 
inherent complexity of a living system presents difficulties in studying the role of 
individual components, as well as in studying the interplay between biochemical and 
biophysical factors. Similarly, traditional in vitro biological assays often require large 
reagent volumes and are performed in a 2-dimensional environment. The advent of 
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microfluidics has allowed for the study of biological systems in a 3-dimensional system 
that gives researchers spatio-temporal control over experimental inputs. Microfluidic 
systems can thereby incorporate some of the global aspects of in vivo models with the 
precise control of traditional in vitro assays. While microfluidics do not replace the utility 
of animal models, microfluidics can serve as complimentary platforms for understanding 
biological processes. 
Microfluidic systems allow for the handling and manipulation of sub-microliter 
volumes of fluids in micron-sized channels, and these devices have found many 
applications, including chemical analysis, lower cost biological assays, and recapitulation 
of physiological systems.  The technology for microfluidic design and fabrication hails 
from the microchip industry, whereby numerous lithography techniques are employed to 
transfer features from a pattern to silicon and glass6—photolithography and electron beam 
lithography (EBL) are used in this work. While silicon and glass have been used in 
microfluidic chips, polymers and plastics are generally preferable due to their transparent 
nature, low cost, and ease of mass production (and thus their disposability). Typically, 
microfluidic templates are made on silicon wafers and then used as a substrate from which 
features are transferred to an elastomeric substrate, in a process termed soft lithography.7 
Polydimethylsiloxane (PDMS) is the material often chosen for soft lithography for its 
transparent nature, low cost, readily altered surface properties, and moderate stiffness (~1 
MPa) that allows it to conformally contact and bond to other substrates,. Here we will 
discuss photolithography and electron beam lithography, and how each fabrication 
technique can be combined with soft lithography to create microfluidic devices.  
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2.2.1 Photolithography  
Photolithography is the transfer of features from a photomask to a given substrate (in 
this case, a silicon wafer coated with a resin) by way of UV light and downstream chemical 
treatment. A photomask is created to the required specifications by simple printing or by 
etching the pattern prescribed by a computer aided design (CAD) file onto a chrome coated 
soda-lime or quartz substrate.  The silicon wafer is spun with photoresist, a chemical 
substrate that is sensitive to UV light exposure (negative photoresist is crosslinked by UV 
light, impeding its removal; whereas positive photoresist is made more soluble upon UV 
light exposure) (Figure 2.3a). A variety of photoresists can be used to achieve different 
feature sizes, and spin curves are available to determine the spin speed and time required 
to achieve different feature heights. The negative photoresist SU-8 is often used in the 
creation of microfluidic devices due its durability and ability to create high aspect ratio, 
straight walled features. Using a mask aligner (oftentimes in a cleanroom), UV light is 
shone through the photomask and the photoresist coated silicon wafer is effectively 
patterned with the CAD features (Figure 2.3b). The silicon wafer is then developed to 
remove soluble photoresist, resulting in the features specified by the photomask (Figure 
2.3c).  Feature size is determined by the resolution of the photomask (generally 1-2 µm), 
the photoresist thickness, and the photolithographic method (contact versus projection). 
Features as small as 40 nm can be achieved via photolithography but this requires 
specialized equipment and extensive fabrication expertise. Typically, contact 
photolithography is used in making microfluidics masters and has a resolution of ~5 µm. 
To achieve robust, reproducible features, microfluids are typically designed to be on the 
order of tens to hundreds of microns and fabrication becomes non-trivial at <5 µm. 
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 Once the silicon wafer is patterned via photolithography, it can be repeatedly used 
as a master from which elastomeric microfluidic devices can be made via soft lithography. 
To reduce the adherence of PDMS to the silicon wafer, and thereby facilitate the clean 
release of cured PDMS, the wafer is made hydrophobic by any number of chemical 
treatments, such as hexamethyldisiloxane (HMDS). Uncured PDMS, usually at a ratio of 
1:10 crosslinker: prepolymer, is poured over the treated silicon master, degassed in a 
vacuum chamber, and cured at 60 C for >3 hours to create a solid, transparent, elastomeric 
substrate (Figure 2.3 d). The patterned PDMS is then cut out and removed from the wafer 
(Figure 2.3e). Individual devices are cut out of the PDMS template and holes are punched 
in the device to serve as inlet and outlet ports (Figure 2.3f).  
 
Figure 2.3: Schematic of fabrication process for microfluidic devices using 
photolithography and soft lithography. (a) SU-8 photoresist is spun onto a silicon wafer. 
(b) UV light is exposed to the photoresist through a photomask or transparency to transfer 
the pattern. (c) Uncrosslinked photoresist is removed using photoresist developer. (d) 
PDMS is poured and cured on the mold. (e) The PDMS is cut and detached from the 
mold. (f) Inlet and outlet holes are punched, and the channel is covalently bonded to a flat 
sheet of PDMS or glass using oxygen plasma. Image taken from [8] 
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To create a sealed microfluidic channel, the PDMS replica of the master is bonded to 
a flat substrate (typically glass or PDMS). PDMS will reversibly bond to PDMS and glass 
due to Van der Waals interactions, but irreversible covalent bonding is often required for 
the pressure induced perfusion of solutions through the channels. Covalent bonding is 
achieved by activating each surface through oxidation in an oxygen plasma cleaner or by 
corona treatment, and placing the two activated surfaces together. Bonding can be further 
enhanced by placing the bonded device on a hot plate at 80 C for 10 minutes. Microfluidic 
channels can then be perfused via gravity driven flow, a syringe pump, or pressure driven 
flow (Figure 2.4). A four-inch silicon wafer can thus be patterned with tens of microfluidic 
devices, and poured with PDMS hundreds of times without significant loss in feature 
resolution. 
 
Figure 2.4. Bonded microfluidic device.  Microfluidic channels bonded to a PDMS 
backing and perfused with an aqueous solution through tubing in inlet and outlet ports. 
Image taken from [9] 
 
2.2.2 Electron Beam Lithography (EBL) 
While complex microfluidic geometries can be achieved using standard 
photolithography, there are significant losses in precision and resolution when using 
contact photolithography to fabricate microfluidic structures at the single micron scale. To 
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recapitulate the biophysical environment of cells, namely the matrices that blood cells 
interact with, robust, single micron geometries are required. Electron beam lithography 
(EBL) utilizes an electron beam to transfer a CAD pattern to a silicon wafer, and can be 
employed to achieve sub-micron feature dimensions. EBL can be used in a projection 
modality, in direct writing, and as a method for material deposition. Direct writing allows 
for 10 nm resolution, 9 though its pixel by pixel etching requires long write times using 
expensive clean room equipment, and is thus best suited for creating a limited number of 
small features. To that end we used direct writing in this work to create arrays of fine 
features that single cells interact with. As in photolithography, the electron beam patterns 
a photoresist, in this EBL process, however, the wafer is further processed to transfer the 
features to the silicon wafer itself. 
 
Figure 2.5. SEM of EBL features.  Surface of silicon wafer etched with 900 nm holes to a 
depth of 3 µm (left). Cross section of holes created via EBL, notable for their smooth side 
walls. The top (slightly thinner) layer is the hardmask which is removed during processing 
(right). 
 
EBL has been incorporated into the process flow for creating microfluidic devices in 
a number of ways, including the direct patterning of PDMS, the creation of a silicon master 
from which a PDMS master can be made for PDMS to PDMS replica molding, and the 
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creation of a silicon master that can be used for soft lithography.10, 11 In this work, the goal 
is to create a silicon mold that is directly compatible with soft lithography, so we aimed to 
create a master in which PDMS could be repeatedly cast and released without loss of 
feature quality.  To readily release an elastomeric material, the side walls of the silicon 
mold must be smooth (Figure 2.5). Once a smooth- walled silicon master is made, the 
master can be treated with HMDS to enhance PDMS release. Soft lithography then 
proceeds as previously described. To create a closed microfluidic device, channels created 
with photolithography can be bonded atop the EBL-patterned features (Figure 2.6). This 
combination of fabrication techniques combines the small feature resolution of EBL with 
the less costly use of photolithography for traditional, large features.  
 
Figure 2.6. Process flow for combining EBL with soft lithography to create enclosed 
microfluidic devices with micron-sized features.  To create an EBL patterned silicon wafer 
that is compatible with soft lithography, SiO2 is first deposited on the wafer surface as a 
hard mask, followed by spin coating of an EBL photoresist. The photoresist is then 
patterned via an EBL photolithography tool and the hardmask is dry etched. The silicon 
wafer is etched through an optimized Nano-Bosch process. The patterned silicon wafer is 
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then treated with HMDS and poured with PDMS. The resulting PDMS structures are 
bonded to a microfluidic channel to create an enclosed device.  
 
2.3  Tools for mechanical response of single cells 
The response of cells to force and mechanical stimulus has been studied using a 
number of different technologies. Methods such as micropipette aspiration, atomic force 
microscopy (AFM), and optical tweezers, have been used to probe mechanical properties 
of cells, including stiffness and visco-elastic deformation.12 Recently, groups have also 
used microfluidic devices to measure mechanical properties in a high throughput manner, 
as well as to leverage differences in cell deformability to physically sort cells and create 
diagnostic platforms.13-15  
Micropipette aspiration can be used to apply a wide range of forces and pressures to 
cells, and their response can be monitored via microscopy. Typically, micropipette 
aspiration applies suction to a cell, and extension of the membrane into the pipettor is 
correlated to the applied pressure. This information is then generally fed into a continuum 
model, where mechanical properties are the read out. Micropipette aspiration can thus be 
used to study the visco-elastic properties of the cell membrane, or the whole cell itself.16 
While micropipette aspiration can be used to measure a range of mechanical properties, 
optical tweezers or optical traps are used to measure forces in the piconewton range, such 
as bond strength. Optical traps employ a highly focused laser beam to hold and manipulate 
dielectric particles; the intensity gradient of the laser physically holds the particle at its 
center.17 Force application causes displacement of the particle from the beam center, and 
at small displacements, the restoring force of the beam can be modeled as a Hookean 
spring. By attaching a dielectric bead to the object of interest (DNA, cell, etc), trapping the 
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bead in the beam, and manipulating the bead position, mechanical quantities such as 
elasticity and bond force can be measured from subnanometer deflections.18 Finally, AFM 
can be used to physically probe the cell surface by bringing a cantilever of known spring 
constant into contact with a substrate. The subsequent deflection of the cantilever is related 
to force. AFM has thus been used to measure elasticity and stiffness of various cell 
components under varied environmental conditions.19, 20 
While AFM and optical tweezers provide precise measures of nano-scale forces and 
micropipette aspiration provides global understanding of cell mechanics, the measurement 
of individual events using these tools are time intensive and suffer from low throughput. 
Researchers have thus turned to microfabrication to increase measurement throughput. In 
the simplest form, transit time and geometry through a microchannel—as measured by 
impedance, high speed imaging, etc—can give insights into viscoelastic parameters of the 
cell as well as stiffness and deformability. Manipulating fluids at the microchannel scale 
by inertial focusing and sheath flow can further improve high throughput sorting of cells 
based on their deformabilities. 21-23 
2.3.1 Red Blood Cell Deformation  
The mechanical properties of RBCs have been extensively studied, in part because 
they lack a nucleus and have relatively few cytoskeletal proteins, and therefore serve as an 
idealized, “simple” cell whose fundamentals can be applied to more complex cells.24 More 
importantly, the hallmark of RBCs is their ability to elastically deform through capillaries 
that have a diameter smaller than that of the RBCs themselves. These significant 
deformations do not affect a RBC’s ability to transport oxygen, nor do they damage healthy 
cells in any appreciable ways (as evidenced by RBC’s 120 day lifespan in circulation). 
 18
Many pathologies affecting RBCs (malaria, sickle cell anemia, etc) directly affect the 
deformability of RBCs. There is thus significant importance in understanding the 
deformation mechanics of RBCs and the consequences of pathological changes on RBC 
mechanics. Many efforts in the realm of RBC mechanics aim to leverage differences in 
deformability toward the use in disease diagnostics. 
 Micropipette aspiration has been historically used both to study the mechanical 
properties of the RBC membrane and the properties of the cell itself. 25 RBC mechanics 
can also be studied by subjecting RBCs to shear flow. Further, due to the relatively 
heterogenous nature of RBC populations, microchannel based analysis of RBCs are 
feasible. There are many experimental studies related to flowing RBCs through a 
constriction to measure aspects of their deformability, such as their cortical tension or 
transit time.26-28 Likewise, many computational studies describe the mechanical properties 
of RBCs as well as the extensive shape changes that RBCs are likely to undergo in vivo.29, 
30 
More recently, studies describe the action of the spleen as a mechanical filter for RBCs 
by creating microdevices and utilizing a bead based filtration system.31-35 The spleen is 
considered to be the most physically challenging deformation (1 µm width x 2 µm height 
x 4 µm length) that RBCs undergo if there are no other underlying pathologies. If cells are 
not able to deform through the interendothelial slits in the spleen, they are removed from 
circulation. Sequestration of RBCs by the spleen in the case of malaria infected RBCs could 
have negative health outcomes, so a better understanding of a RBCs ability to deform in 
the spleen is warranted. Computational findings suggest that the most significant 
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determiner of RBC deformability is not the stiffness, but rather the surface area to volume 
ratio. 
Many microfluidic systems now exist to gauge red blood cell deformability. Some are 
aimed at gaining a more global understanding of deformation mechanics, including the 
shape changes that RBCs undergo throughout the deformation processes. Others seek to 
leverage microfluidics for clinical purposes: for instance, a filter to be used in transfusion 
medicine that would remove older, less deformable RBCs. Elastic fatigue was also recently 
studied to show that repeated passage through a constriction reduces the cell’s future 
deformability. The authors aim to correlate this fatigue to different disease states.36 A 
recent set of studies also sought to understand the relationship between relaxation time and 
time exposed to a force (or time in a constricted state), and it was found that there is a 
critical load time of T~ 180 s at which the relaxation time was significantly extended from 
0.1 s to 10 s. 37, 38  
While the wealth of knowledge garnered by these studies gives significant insight into 
deformation (and sometimes hemolysis), there is still a complete lack of knowledge as to 
the mechanism or real-time biophysical parameter space of RBC fragmentation (the 
breaking of RBCs into two disparate cell fragments) and its temporal requirements (outside 
of shear induced hemolysis). Typically, the presence of RBC fragments is mentioned in 
publications as an aside, such as when RBCs were passed through a long filter with small 
pore size.35 Understanding this process is important as RBC fragmentation is a hallmark of 
a number of diseases and also of device implants. The morphological abnormalities that 
are seen on clinical blood smears are described below.  
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 RBC Morphological Abnormalities 
 
Mature red blood cells are anuclear, featuring a lipid bilayer traversed by 
transmembrane proteins (primarily glycophorins and protein 3) bound to a complexly 
networked spectrin cytoskeleton. RBCs are typically disciform in shape with an average 
diameter of 7.5 µm. When visualized by traditional pathology stains, RBCs exhibit a light 
central region (central pallor) one third the cell size. Various morphological abnormalities 
result from pathological states that alter the RBC membrane or cytoskeleton and/or from 
mechanical damage to the cells (Figure 2.7). Typical RBCs are described as normocytic 
(of normal size) and normochromic (of normal coloring, and thus normal haemoglobin 
content). Morphological abnormalities are then described via peripheral blood smears 
based on: size of central pallor; increase or decrease in cell size; and alterations in shape 
(e.g., spherical, fragmented,  and spiculated).39 Clinical diagnoses and treatment courses 
are based on the presence of these abnormalities, and thus a brief description of the 
morphologies related to mechanical disruption, is warranted: 
- Tear drop cells (dacrocytes) are shaped as named and are primarily linked to bone 
marrow fibrosis, in which there is increased deposition of reticulin and collagen 
fibers. It has been posited that these cells form either when released from the 
abnormal bone marrow matrix or that the newly formed RBCs are fragile and are 
damaged in the spleen.40  
- Spiculated cells describe various abnormal RBCs that are characterized by a lack 
of roundness and the presence of spicules of different size and number. The short, 
blunt spicules that characterize echinocytes (also referred to as burr cells) often 
result from electrochemical interactions and ATP depletion; this damage is 
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generally reversible upon reestablishing a favorable chemical environment. 
Acanthocytes display large, irregular spicules and are indicative of many inherited 
and acquired diseases that increase the ratio of cholesterol to phospholipids.  Of 
note are keratocytes and schistocytes, these cell fragments are characterized by 
irregular edges and are indicative of mechanical damage caused by 
microangiopathies—diseases that cause clotting in the microcirculation.  
- Spherocytes and microspherocytes are indicative of an alteration in the surface 
area to volume ratio of the RBC that causes them to assume a spherical shape. They 
are identified on blood smears by lack of central pallor and a reduced diameter. 
Spherocytes can result from pathologies that alter the cell membrane or 
cytoskeleton, or can be a byproduct of schistocyte formation. 
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Figure 2.7 Chart of RBC morphological abnormalities. Pathologists categorize abnormal 
RBC morphology based on size variation, hemoglobin distribution, and shape variation. 
Spherocytes, helmet cells, schistocytes, tear drop cells, and burr cells are all thought to 
arise from mechanical damage to RBCs.  Image taken from [41]  
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CHAPTER 3: RESOLVING THE MECHANISM OF THE FERRIC 
CHLORIDE THROMBOSIS MODEL 
3.1  Introduction and Background 
In the most commonly used animal model for studying thrombosis (the ferric 
chloride (FeCl3)-induced thrombosis model), FeCl3 is applied to the adventitia of a mouse 
blood vessel, and the resulting occlusive clotting is monitored by Doppler flow 
measurements and/or intravital microscopy.42-46 This injury model has been used 
extensively to test the efficacy of therapeutics and to determine the relevant receptor/ ligand 
interactions for clot initiation and propagation.47, 48 However, there are discrepancies in 
literature findings that stem, in part, from the various FeCl3 concentrations used and 
differences in the vessels to which FeCl3 is applied (see Table 3.1 for percent solution to 
concentration for anyhydrous and hexahydrate FeCl3). To explain these discrepancies, it 
has been posited that different ligand/ receptor interactions are involved in vessels with 
different shear environments. While this may be valid, the concentration dependent nature 
of the FeCl3 model implicates a role for mass transfer in the system.  
Clot initiation in this model is historically attributed to free iron-induced 
denudation of endothelial cells and the subsequent exposure of the subendothelium that 
triggers platelet adhesion/aggregation and activation of the coagulation cascade.48 
However, studies using mice deficient in collagen receptor glycoprotein VI have produced 
contradictory results, reporting both normal and altered thrombus formation.49, 50 Eckly et 
al. observed that although endothelial cells appear denuded and platelets are present in the 
occlusive thrombus, there is limited collagen exposure in the vessel.51 Further, an elegantly 
designed SEM analysis revealed that endothelial cells are not denuded, and surprisingly, 
 24
that erythrocytes mediate the adherence of platelets to the endothelium by an unknown 
mechanism.52 In addition to the uncertain status of the endothelium, the effects of FeCl3 
vary based on the vessel to which it is applied: in mice lacking the extracellular domain of 
GPIbα, the FeCl3 model results in occlusion in mesenteric venules but not in the carotid 
artery.49, 53 These inconsistencies, in conjunction with the wide range of published FeCl3 
concentrations (10 mM to 2 M) and application times (1-20 min) used to elicit a clotting 
response, raise questions about the direct chemical effects of FeCl3 on blood components 
and the role that mass transfer plays in this thrombosis model.54 
Table 3.1. Percent solution (w/v) of FeCl3 in terms of concentration (M). 
In the literature, ferric chloride amount is expressed in terms of percent solution, but as 
both anhydrous ferric chloride (162.2 g/mol) and ferric chloride hexahydrate (270.3 g/mol) 
are used, concentration must be specified in molarity for consistency and comparability. 







Microfluidic devices allow for spatiotemporal control over the introduction of a 
precise chemical concentration in defined shear environments. This control then allows for 
the role of mass transfer in this injury model to be elucidated, a feat not readily achievable 
in vivo. Furthermore, an in vitro system allows for piecewise introduction of blood 
components into the system to determine the role that each part of the complex blood 
environment plays in the ferric chloride thrombosis model. Discrepancies in the literature 
and the extensive use of the FeCl3 model makes understanding its mechanism of utmost 







0.5 0.031 0.018 
1 0.062 0.037 
5 0.308 0.185 
10 0.617 0.370 
20 1.233 0.740 
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understanding the role of mass transfer in the injury model using microfluidics not only 
reconciles inconsistencies in the literature, but informs researchers as to the appropriate 
uses of the injury model in the future. 
3.2  Materials and Methods 
3.2.1 Experimental Reagents 
Human blood was collected according to IRB-approved protocols per the Declaration 
of Helsinki into sodium citrate (BD). Blood was separated into its individual components 
by centrifugation: washed RBCs were obtained by centrifugation of whole blood at 300g 
for 10 min (followed by 3x PBS wash), PRP was obtained by centrifugation at 150g for 10 
minutes with no brake or acceleration, and PPP and platelets were obtained by 
centrifugation of PRP at 900g for 5 minutes with no brake or acceleration. To study whole 
blood, RBCs were diluted in PRP to 12.5% to allow for improved microscopy and 
visualization of clot components. To recalcify blood, CaCl2 (Sigma) was added to a final 
concentration of 0.01 M directly prior to every experiment, unless otherwise noted. Where 
appropriate, blood samples were incubated for ~5 minutes with Alexa-Fluor-568 
conjugated fibrinogen at 10% v/v, mouse anti-human CD41, M148 (Abcam, Cambridge, 
UK) at 1:400, and AlexaFluor-488 goat-anti-mouse IgG at 1:400 (Life Technologies, 
Carlsbad, CA). Human umbilical vein endothelial cells (HUVEC, Lonza, Walkersville, 
MD) were stained with Hoescht 33342 (Life Technologies) prior to experiments. Live/dead 
assay was performed with calcein and propidium iodide in serum-free EGM-2 media 
(Lonza). PBS with calcium and magnesium pH 6.5 was used to dilute anhydrous iron(III)-
chloride (Sigma), aluminum (III) chloride (Sigma), and chromium (III) chloride (Sigma) 
to the desired concentration on the same day as the experiment.  
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3.2.2 Microfluidic Parameters 
To recapitulate the endothelium-blood-FeCl3 interface, a polydimethylsiloxane 
(PDMS) based T-shaped microfluidic was designed with a 250 mm width main channel, 
50 mm width side channel, and overall device height of 50 mm. Device mold was 
fabricated via traditional photolithography and devices were made via traditional soft 
lithography. Devices were bonded after exposure to oxygen plasma. To obtain desired flow 
profile, two Harvard Apparatus pumps were used to infuse fluid at 2.7 μL/ min in the main 
channel and 0.4 μL/min in the small channel, giving a shear rate of ~ 4 dyne/cm2 at the 
interfacial region in the main channel. Non-endothelialized devices were blocked with 3% 
BSA for 1 hour prior to experiments. When appropriate channels were seeded with 
HUVEC cells and cultured in EGM-2 media (Lonza), as previously described.9 
 
3.2.3 Flocculation Experiments 
To visualize blood cell aggregation, 5 μm of the blood component of interest was 
pipetted on a glass cover slip, 5 μm of FeCl3 at a given concentration (from 5 µM to 1 M) 
was pipetted on top of the blood, a top cover slip was placed on the sample, and 
microscopic analysis was immediately performed. To perform light scatter measurements, 
250 μL of FeCl3, AlCl3, or CrCl3 at various concentrations was added to 250 μL of blood 
components in fluorimeter cuvettes (Sigma). Light scatter was measured for 60 seconds at 
600 nm by a PTI Fluorescence System Fluorimeter immediately after chemical addition.   
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3.2.4 Drug treatments and mouse experiments 
Blood and endothelialized devices were incubated with drug treatments for 30 minutes 
prior to experiment. Aspirin (Sigma) was used at 1 mg/mL, heparin (APP Pharmaceuticals, 
LLC, Schaumburg, IL) at 1 UN/mL, hirudin  (Sigma) at 1 UN/mL, and eptifibatide (COR 
Therapeutics, San Francisco) at 10 μM. vWF deficient blood was created by adding healthy 
donor washed platelets and washed red blood cells to vWF severe trait 3 plasma (George 
King Biomedical, Inc., Overland Park, Kansas). C57BL/6 mice (Jackson Laboratory) were 
used for all wild-type controls, and IL4-R/Iba (glycoprotein Ib-α–deficient) 55 were 
provided by Jerry Ware. Mouse cardiac punctures were performed following IACUC 
approved protocols, and mice were approximately 8 weeks old at the time of experiment. 
To analyze differences in occlusion, we performed a two-tailed, unpaired 
(student’s) T-test for equality of means between treated blood and control blood with a 
confidence interval of 95% (values are significantly different when p<0.05). Tests were 
performed between treated blood at a given concentration and untreated blood at that same 
concentration (control blood with 50 mM FeCl3 vs. aspirin-treated blood with 50 mM 
FeCl3).   
3.2.5 Computational Fluid Dynamics Modeling 
I used COMSOL Multiphysics, version 4.4, to simulate simple blood flow in a vessel. 
I modeled the blood vessel as 2D and used the “laminar flow package” to simulate an 
incompressible fluid with water-like properties (similar viscosity and density). My model 
included three domains: an upstream region (1 mm in the y-direction), the ferric chloride 
patch region (1 mm in the y-direction), and a downstream region (1 cm in the y-direction). 
For each vessel type, I used the diameter and velocity from the literature and specified a 
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no-slip boundary condition at the walls.  I simulated the diffusion of ferric chloride using 
the “transport of diluted species package” which solves the convection-diffusion equation. 
The initial value of ferric chloride was set to 0 throughout the three domains as well as at 
the inflow boundary. At the upper boundary of the ferric chloride patch region, the 
concentration of ferric chloride was set to 50 mM (the previously calculated luminal 
concentration). The diffusion coefficient was set to 6.0 x 10-10 m2/s. I ran the simulation to 
visualize the diffusion of ferric chloride in the vessels (solution time 16-20 s). I set a manual 
data range in the plot options of 0.5 mM to 50 mM, to present the concentrations at which 
ferric chloride induces blood aggregation. Shear stress was also modeled in the vessel to 
be approximately 4 dyn/cm2 at the interfacial region. 
3.3  Results and Discussions 
3.3.1 Creation of an In Vitro Endothelial Cell/ Blood Cell/ Ferric Chloride Interface 
Traditional photolithography and soft lithography were used to create a T-junction 
microfluidic device that would allow for spatiotemporal control of the introduction of 
FeCl3 through a side channel to interface with blood components perfused through a main 
channel (Figure 3.1). This system allows for the two species to interface near the wall, as 
they would in the convection dominated environment of blood vessels. As previously 
developed in the Lam engineering and hematology laboratory, the main channel can also 
be seeded with endothelial cells to a confluent monolayer that further recreates the 
multifaceted in vivo environment.9, 56 With this addition, sundry combinations of biological 
factors can be introduced to the system to elucidate the effects of FeCl3 on each component 




Figure 3.1. T-junction microfluidic recapitulates the FeCl3 interface.  A) “Endothelial”-
ization of the main channel of T-junction microfluidic results in a blood cell/ ferric 
chloride/ endothelial cell interface that can be visually monitored via wide field 
fluorescence microscopy. B) Microscope images of the bare channel (left), an 
endothelialized channel (center), and the interface of the fluid streams from each inlet 
(right). The interface is depicted by a cartoon of the model system: FeCl3 patch is applied 
to the adventitia of a blood vessel. FeCl3 diffuses through the vessel wall and into the 
lumen. Scale bars are 50 µm. 
 
The main channel is 250 µm wide and 50 µm in height and perfused at 2.7 µL/min, while 
the side channel is 50 µm wide and 50 µm in height and is perfused at 0.4 µL/min; 
resulting in a shear stress of ~4 dynes/cm2 at the interface, as modeled by computational 




Figure 3.2. Shear Stress in T-junction Fluidic.  A COMSOL model of shear stress and 
streamlines in the designed T-junction microfluidic shows the experimentally verified fluid 
interface with a shear stress of ~4 dyn/cm2 in the interfacial region. 
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3.3.2 Calculation of Relevant FeCl3 Concentration for Microfluidic Influx 
A saturated 1 M FeCl3 patch is applied to the adventitial side of the mouse carotid 
artery to induce robust thrombus formation. This concentration, however, is not the 
concentration of interest for the microfluidic system; the concentration needed for in vitro 
studies is that at the vessel lumen where the FeCl3 interfaces with the endothelial cells and 
blood. To obviate complex modeling of FeCl3 diffusion through the multilayered vessels, 
the bulk in vivo FeCl3 concentration was measured downstream of the patch. The left 
carotid artery of a mouse was exposed by dissection, and injured by topical application of 
filter paper saturated with 1 M (20% anhydrous) FeCl3—for 2, 5, or 10 minutes. The 
adventitia of the artery was then rinsed with saline to halt FeCl3 influx, and 400 μL of blood 
was drawn downstream of the patch and iron content was measured. To account for 
measurement error due to iron binding to blood components, the assay was performed with 
a known amount of FeCl3 in buffer and in plasma, absorbance measurements were 
obtained, and a correction factor of 10 between the solutions was found. The downstream 
iron concentration was found to be 160 µM or 9 µg/mL. Steady-state FeCl3 flux into the 
vessel was reached by 5 minutes and maintained at 10 minutes; the input concentration is 
thus assumed to be constant over the relevant time scales (Figure 3.3). 
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Figure 3.3. In vivo ferric concentration downstream of FeCl3 patch. 1 M FeCl3 patch is 
applied to carotid artery for 2, 5, and 10 minutes, and the downstream iron concentration 
is measured. Steady-state downstream concentration is found to be ~160 µM.  
 
Fick’s laws of diffusion in a convection dominated system were used to find the 
endothelial wall concentration. Given the high shear rates and the approximately linear 
velocity profile near the wall, it was assumed that the contact time of the blood with the 
patch area is short and a short-contact-time solution of the Navier Stokes equation can be 
used. The solution for the flux of the solute into the blood along the wall where the patch 
is located is then: 
 




where D= 6 x 10-5 ± 1 x 10-5 cm2 /s  is the diffusion coefficient of FeCl3 in blood 57, R=250 
± 25 μm is the vessel radius 58, 59, Vz = 20 ± 2 cm/s is the average blood velocity 60, 61, and 





























or when convection dominates over diffusion.62 Integrating the equation for flux across the 
area of the patch gives the total solute flux into the blood vessel, which (assuming there is 
no uptake of solute along the vessel) must equal the experimentally calculated solute flux 
downstream. The initial concentration at the vessel wall, and the relevant concentration for 
the in vitro input, is then C0 ~ 50 mM FeCl3 (Figure 3.4).  
 
 
Figure 3.4. Relevant system concentrations. By measuring the in vivo iron concentration 
downstream of the FeCl3 patch, the luminal wall concentration—that at the interface of the 
blood and endothelial cells—can be found via Fick’s Laws of Diffusion. The FeCl3 
concentration at the interface is approximately 50 mM when a 1 M patch is applied. 
 
3.3.3 Effects of FeCl3 on the In Vitro “Vasculature” 
The endothelialized T-junction from Section 3.2 aptly recreates the in vivo effects of 
the FeCl3 injury model: whole blood exposed to 50 mM FeCl3 results in a channel 
occluding aggregate without endothelial cell denudation (Figure 3.5). In agreement with 
the findings of Barr et al, RBCs appear to be a significant component of the aggregate.52 
This is surprising as RBCs are not thought to be directly involved in the biochemically 
regulated clotting cascade. Interestingly, FeCl3 leads to aggregation of all individual 
blood components: washed RBCs, platelet rich plasma (PRP), platelet poor plasma (PPP), 
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and platelets (Figure 3.5). FeCl3 even leads to the aggregations of bovine serum albumin 
(BSA), a protein uninvolved in clotting (Figure 3.6). 
 
 
Figure 3.5. Blood components aggregate in the presence of FeCl3 in endothelialized 
microfluidic channel. When whole blood, red blood cells, platelets, plalelet poor plasma 
(PPP), and platelet rich plasma (PRP) are exposed to 50 mM FeCl3 they form channel 




Figure 3.6. BSA aggregates when exposed to FeCl3.  3% BSA forms aggregates when 
exposed to 50 mM FeCl3 in endothelialized microfluidic.  
 
While the endothelial cells remain adherent to the microfluidic channel surface, FeCl3 




Figure 3.7. Dose-dependent FeCl3-induced endothelial cell death.  Endothelial cell 
viability is dependent on the concentration of FeCl3 that cells are exposed to: higher input 
concentrations result in localized cell death, but not denudation. Panels from left to right 
show introduction of 5 mM, 50 mM, 500 mM, 1 M FeCl3, respectively. Green/live: calcien; 
red/dead: propidium iodide. Scale bars represent 50 µm. 
 
3.3.4 Effects of FeCl3 on Blood in the Absence of Endothelial Cells 
The aggregation of blood components that are outside of the traditional clotting 
cascade (RBCs and blood proteins) suggests that aggregation might not be initiated by 
endothelial cell injury. The in vitro system allows the physiochemical effect of FeCl3 to be 
studied in the absence of endothelial cells, giving mechanistic insight that is not possible 
in vivo. Surprisingly, FeCl3 causes aggregation of all blood components, in the absence of 
endothelial cells (Figure 3.8). 
 
Figure 3.8. Blood aggregates in bare microfluidics. Representative images of blood 
component aggregates (whole blood, RBCs, platelets, PRP, PPP, BSA) in non-
endothelialized microfluidics when exposed to 50 mM FeCl3. The presence of sheet-like 
protein aggregates is clearly visible in PPP. All scale bars represent 50 μm. 
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Washed platelets and RBCs are slowest to aggregate, and the protein component of blood 
(PPP) forms sheet-like structures that appear to enhance aggregate initiation and stability 
when cells are present (PRP and WB). At 1 M FeCl3, all blood components form a fully 
occlusive aggregate (Figure 3.9). The aggregation of all blood components in the absence 
of endothelial cells suggests that the mechanism of aggregate initiation is outside the 
traditional clotting cascade. 
 
Figure 3.9. Time to aggregate initiation and stabilization in bare microfluidics.  Aggregates 
of washed RBCs, washed platelets, PPP, PRP, and whole blood (WB) form in microfluidic 
channels at all concentrations ranging from 50 mM to 1 M. Time (in seconds) to initial 
adherence of blood components and stable aggregate formation (unchanging or complete 
occlusion) is shown, where complete channel occlusion is denoted by cross-hatched bars. 
3.3.5 Proposed Mechanism of FeCl3-induced Aggregate Initiation 
As FeCl3 causes aggregation of blood cells and proteins, both in the presence and 
absence of endothelial cells, a non-biological, charge-based mechanism of aggregation was 
proposed (Figure 3.10). Blood is a colloidal suspension of negatively charged cells and 
 36
proteins, and FeCl3 is used in applications such as waste water treatment to destabilize 
colloidal suspensions by reducing the zeta potential of the particles, and causing them to 
aggregate.63,64 In aqueous solutions FeCl3 continuously hydrolyzes, polymerizes, and 
precipitates; the species exists primarily as Fe3+, Fe(OH)2+, and Fe2(OH)24+. 65,66 Fe3+ is a 
strong trivalent cation that can directly bind to negatively charged proteins (both cell bound 
and in solution), and lead to their destabilization and aggregation (termed flocculation in 
colloidal chemistry).67 The cationic hydroxides, on the other hand, deposit on surfaces and 
create a large particular mesh that can bind negatively charged particles.68 Together, these 
charge-based mechanisms cause the aggregation of colloids such as blood cells.  
 
 
Figure 3.10. Charge-based aggregation of blood components. Cartoon representation of 
the action of Fe3+ as it interacts with negatively charged blood cells. “Ferric ions permeate 
through the endothelium into the lumen. These positively charged ions suppress the 
negative charge on blood cells, endothelial cells, and plasma proteins, which allows them 
to form agglomerates. This charge-based mechanism allows blood cells and proteins to 
accumulate on the vessel wall independent of hemostatic mechanisms.” 69 
 
To test this charge-based hypothesis, another metal salt used in flocculation, 
AlCl3, was introduced to the system. Al3+ has similar binding properties to Fe3+, and in 
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support of my hypothesis, it too causes RBC aggregation in both bare and endothelialized 
channels. Further, AlCl3 was recently shown to induce thrombosis in vivo when used in a 
similar manner to FeCl3.70 Alternatively, introduction of CrCl3, a trivalent cation that is 
considered chemically inert because it preferentially binds water, does not cause blood 
cell aggregation.63, 65, 71 FeCl3, AlCl3, and CrCl3 all cause endothelial cell death likely due 
to their highly acidic nature, but as shown, they do not have similar aggregation 
capabilities, thus providing further evidence that cell death alone is not enough to initiate 
extensive aggregation (Figure 3.11). 
 
 
Figure 3.11. AlCl3 causes RBC aggregation similar to FeCl3.  The introduction of AlCl3 
causes RBCs to aggregate at the fluidic interface in bare (left) and endothelialized (middle) 
microfluidics. AlCl3 causes endothelial cell death, but the cells remain adherent (right). 
The introduction of CrCl3 does not result in RBC aggregation in bare (left) or 
endothelialized (middle) microfluidics. CrCl3 causes endothelial cell death, but the cells 
remain adherent (right) (green/live- calcien, red/dead- propidium iodide). All scale bars 
represent 50 μm. N=3. 
 
FeCl3-induced aggregation of blood cells and proteins also proceeds in static 
flocculation assays. Standard microscopy shows extensive aggregation of blood cells and 
proteins for concentrations of FeCl3 greater than 0.5 mM, and FeOH precipitates are visible 
as mesh-like deposits at low FeCl3 concentrations (the hydroxide species predominates in 
less acidic environments) (Figure 3.12).  
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Figure 3.12. Microscope analysis of flocculation activity of FeCl3. Static aggregation of 
blood components (RBCs, PPP, and PRP) increases in a concentration dependent manner 
from 0.005 mM to 1 M FeCl3. At mid-range concentrations of FeCl3, amorphous iron 
hydroxide precipitates are present. Sheets of protein are evident in concentrations greater 
than 5 mM. Platelets (green: CD41); fibrinogen (red). Scale bar = 50 µm, N=3. 
 
 
Dynamic light scattering, as measured by a fluorimeter—where increased light scattering 
correlates to increased aggregate presence—show that FeCl3 and AlCl3 cause aggregation 
of PRP and PPP (Figure 3.13). At high concentrations, the addition of FeCl3 and AlCl3 
results in a solid, macroscopic protein aggregate (Figure 3.14).  
 39
 
Figure 3.13. Light scattering of PRP and PPP when exposed to a range of FeCl3, AlCl3, 
and CrCl3 concentrations.  Values are expressed as fold increase over control PPP and PRP, 
where increased scatter corresponds to increased aggregation. All scale bars represent 50 





Figure 3.14. FeCl3 and AlCl3 –induced aggregation of blood components in microcuvettes.  
PRP is exposed to 0.005 mM to 1 M FeCl3 (top). Aggregates are macroscopically visible at 
concentrations > 0.5 mM. PRP with both 500 mM and 1 M FeCl3 forms a solid aggregate 
that is not disturbed upon microcuvette inversion. PRP is exposed to 0.005 mM to 1 M 
AlCl3. Aggregates are macroscopically visible at concentrations > 50 mM. PRP with 1 M 
AlCl3 forms a solid aggregate that is not disturbed upon microcuvette inversion (right). 
Washed RBCs are exposed to 0.005 mM to 1 M FeCl3 (bottom). Aggregates are 
macroscopically visible at concentrations > 0.5 mM.  Washed RBCs with 50 mM, 500 mM, 
and 1 M FeCl3 form a solid aggregate that is not disturbed upon microcuvette inversion 
(right). 
 
The non-ergodic nature of aggregates (the aggregate being large compared to the 
incident light beam) at high chemical concentrations, and for erythrocyte suspensions, 
makes light scattering measurements inaccurate, but aggregation at these concentrations is 
clear both macro and microscopically.72 Conversely, CrCl3 does not result in aggregation 
in any of these assays. My findings suggest then that the aggregation of blood components 
in this model is due to charge-based mechanisms: the direct inner sphere binding of Fe3+ 
to plasma proteins and cell membrane–localized proteins, as well as binding of cells to 
FeOH precipitates. Importantly, conventional clotting occurs in concert with FeCl3 induced 
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aggregation: at t=0, light scattering of FeCl3-treated PRP is three times that of untreated 
PRP, but at t=20 min, both FeCl3-treated and untreated PRP plateau at seven times the light 
scattering of PRP at t=0 (Figure 3.15). Further, we found that aggregation is similar in the 
presence and absence of physiologically relevant concentrations of the covalent ions Ca2+ 
and Mg2+(Figure 3.16).  
 
 
Figure 3.15.  Physiological clotting occurs in addition to FeCl3-induced aggregation. At 
t=0, PRP + 0.5 mM FeCl3 scatters approximately three times as much light as PRP. After 
a 20 minute incubation, PRP and PRP + 0.5 mM FeCl3 reach the same level of aggregation 




Figure 3.16. Light scattering of PRP with Ca2+and Mg2+.Light scattering was similar 
between PRP samples with and without the addition of calcium ions.  
3.3.6 Determining the Role of FeCl3 in Altered Hematological Environments 
While the experiments performed implicate a charge-based mechanism of blood cell 
aggregation, in vivo, the FeCl3 injury model has utility in studying clotting: clotting can be 
mitigated by the administration of therapeutic antithrombotic agents, as well as in knock-
out mice whose clotting mechanisms are hindered.73-76 This would suggest that, in addition 
to charge-based aggregation, the clotting cascade plays a role in the FeCl3-induced 
thrombosis injury model. Altered clotting environments can be recreated in vitro and 
effects similar to those shown in vivo can be seen: cell aggregation and channel occlusion 
is mitigated when blood is pretreated with therapeutic antithrombotic agents and then 
exposed to 50 mM FeCl3. However, when the FeCl3 concentration is increased to 500 mM, 




Figure 3.17. Aggregation of blood in altered clotting environments.  In bare microfluidics, 
all drugs and phenotypic abnormalities lead to significant decreases in channel occlusion 
at 50 mM (P < 0.5) compared with the control solution, but 500 mM FeCl3 overcomes the 
protective effect of aspirin, heparin, and hirudin In endothelialized microfluidics, drugs and 
phenotypic abnormalities lead to significant decreases in occlusion at 50 mM (P < 0.5), but 
500 mM FeCl3 overcomes the protective effect. Solid bars represent patent channels 
whereas the slant pattern represents flow cessation. There was not a significant difference 
in occlusion between untreated control blood exposed to 50 mM and that exposed to 500 
mM. Significance is denoted by an asterisk (*), and was measured by a 2-tailed, Student t-





Figure 3.18. Blood cell aggregation in treated conditions. Representative images from drug 
treatments in bare and endothelialized microfluidics, at 50 mM and 500 mM. Platelets 
(green: CD41), fibrinogen (red), endothelial cells (blue).  
 
Further, while blood from wild type mice formed an occlusive aggregate in the 
microfluidic when exposed to 50 mM FeCl3, blood from mice lacking integrin GPIb-α (to 
bind vWF, a clotting factor) formed loose aggregate networks and vessel patency was 
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maintained, though aggregation was still extensive (Fig. 6D).  I hypothesize that “at 
increasing FeCl3 concentrations, pharmacologic inhibition does not effectively prevent 
channel occlusion because, although the clotting cascade is compromised, the FeCl3 




Figure 3.19. Aggregation in GPIb-alpha knock-out mice  In bare and endothelialized 
channels, IL4-R/Iba blood forms fewer aggregates at 50 mM FeCl3 than WT blood, and 
the channel remains patent. Representative image of WT blood and IL4-R/Iba blood 
aggregation in the microfluidic channel. All scale bars represent 50 μm; N = 4. Solid bars 
represent patent channels while the slant pattern represents flow cessation. Significance is 
denoted by an asterisk (*), and was measured by a 2-tailed, Student t-test between the 
treatment condition and its paired control (eg, 50 mM control and 50 mM aspirin). 
 
3.3.7 Elucidating the Role of Mass Transfer in the FeCl3 Injury Model 
The extent of blood cell aggregation in the FeCl3 injury model is highly dependent on 
the concentration of FeCl3 throughout the vessel. This concentration varies based on the 
concentration applied to the vessel, properties of the vessel wall itself (thickness, 
composition, etcetera), and the fluid environment in the vessel. While the first two factors 
are outside of the scope of this study, the blood velocity and diameter of different blood 
vessels that FeCl3 is applied to in the literature are considered. To determine how the 
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chemical concentration varies radially downstream of the patch site in different vessel 
types, I performed computational fluid dynamic (CFD) simulations for mass transfer of a 
dilute species using COMSOL (Figure 3.20). In small vessels, and those with lower blood 
velocities, the effective concentration that leads to aggregation (0.5 mM, as determined by 
in vitro experiments) is present across a larger extent of the vessel: in the carotid artery, 
the chemical reaches 12% of the vessel diameter, while in the mesenteric veins, it reaches 
40% of the vessel. The extent of FeCl3-induced clotting is then governed by mass transfer 
within different vessel types. This insight from mass transfer begins to resolve differences 




Figure 3.20. Mass transfer of FeCl3 in relevant vessels. The role of vessel parameters 
(diameter and blood velocity) on transport of ferric chloride within the vessel was explored 
via COMSOL modeling. To focus on the role of mass transfer in the lumen, it was assumed 
that the intraluminal near-wall concentration was 50 mM for all vessel types; in other 
words, we ignored possible differences in diffusion of ferric chloride through the wall of 
the three vessel types. (A) The ferric chloride concentration profile in different vessels, 
where only concentrations greater than 0.5 mM are plotted (the concentration at which we 
have shown ferric chloride induces aggregation). (B) Zoomed in view of the concentration 
profile at the edge of the ferric chloride patch. The mesenteric vein has the largest span of 
concentrations over the largest vessel percentage due to its relatively low velocity of 0.3 
cm/s. 
 
3.4  Conclusions 
Using the in vitro T-junction microfluidic system, I studied the effect of FeCl3 on 
individual blood components and discovered that clot initiation and initial cell aggregation 
are due to complexation between negatively charged blood cells/ proteins and the 
positively charged iron species. Introducing therapeutics into the system allowed me to 
show that once clotting is initiated by FeCl3 it continues by the standard clotting cascade, 
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but that the difference between concentrations that causes these disparate effects is small 
(Figure 3.21). These findings account for the varied results in literature for different injury 
models and different application locations and procedures, especially given the inability to 
tightly control FeCl3 concentration in vivo. 
 
Figure 3.21. Two-phase mechanism of ferric chloride injury model.  In the first phase, 
negatively charged RBCs bind to positively charged iron species and adhere to the 
endothelial surface. There are few proteins and platelets associated with the bound 
material. In the second phase, adherent blood cells and damaged endothelial cells initiate 
biological clotting cascade. Proteins and platelets are more abundant in the aggregate in 
this phase. Fibrinogen is shown to form a boundary layer at the distal edge of the aggregate. 
 
“The controlled reductionist environment afforded by the in vitro endothelialized 
microfluidic system allows for precise control over FeCl3 induced thrombosis and led me 
to propose a novel, two-phase mechanism for the action of FeCl3 in thrombus formation. 
The first phase is independent of typical biological “clotting,” and consists of the FeCl3 
concentration- dependent binding of negatively charged blood cells and proteins to 
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positively charged iron species. The adherent cells from the first phase initiate the second 
phase, the standard biological clotting cascade. Where one phase ends and the other begins 
is non-trivial to determine, as the effective FeCl3 concentration in the channel (which 
determines the extent of the first phase) is dependent on mass transfer phenomena both 
through the vessel wall and in the vessel itself. Researchers should take caution that this 
will affect their findings, especially in small vessels, and that aggregation phenomena that 
seemingly suggest a novel ligand/receptor interaction may in fact be due to non-specific 
charge based-binding effects.” 77 The results and figures presented in this chapter were 





CHAPTER 4: DESIGNING MICROFLUIDIC DEVICES TO 
EXPLORE THE INTERACTIONS OF BLOOD CELLS WITH 
BIOPHYSICAL MATRICES 
4.1  Introduction  
Blood cells encounter a number of matrices: platelets transit nascent fibrin clots, red 
blood cells are filtered through the spleen’s interendothelial splenic slits, and white blood 
cells extravasate through endothelial cell gaps. Biochemical aspects of cellular process are 
well characterized, but more recently, it has been shown that cells dynamically sense and 
respond to biophysical cues such as substrate stiffness and geometrical constraints; 
physical cues even direct cell differentiation and stem cell lineage.1, 78 Blood cells pass 
through, and interact with, biological matrices such as fibrin clots and the vascular wall, 
but the physical and biochemical aspects of these interactions are largely indistinguishable 
from one another in vivo. As such, there is a gap in knowledge as to how RBCs deform 
through geometrically challenging matrices and how blood cells in general activate and 
respond to matrices as they transit them. The biological matrices that blood cells typically 
transit are on the size scale of hundreds of nanometers to single microns, both in terms of 
pore/ gap size and fiber diameter.32, 79, 80 To begin to better understand the activity of cells 
when challenged by such matrices, a suite of microdevices was designed and fabricated to 
allow for real-time visualization of single cell/ matrix interactions. Creating features of 
these dimensions using traditional photolithography is non-trivial, so a silicon wafer was 
templated by electron-beam lithography (EBL) and then directly poured with 
polydimethylsiloxane (PDMS). A standard microfluidic channel can then bonded on top of 
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the array to create a sealed device through which blood components are perfused. To that 
end, we created a micropillar array to recapitulate the deformation of cells through 
individual matrices of “fibers” as well as a microcanal array that requires cells to deform 
in a tightly confined geometry over different time scales (this also corresponds to 
monitoring the response of cells to  steep pressure drops at the point of constriction). 
4.2  Materials and Methods 
4.2.1 Device design 
Microfluidics were designed to recapitulate the interactions of single cells with 
vascular matrices; the simplest controlled realization of these interactions can be described 
by the movement of cells through a pillar array with “fiber” size of 900 nm and gap size of 
2 µm. These dimensions are on the size scale of physical geometries of diverse vascular 
matrices and PDMS is of a similar stiffness of various matrices, including fibrin clots, 
endothelial cell gaps, and splenic slits.32, 79, 80 Micropillar arrays have previously been 
fabricated both in silicon and PDMS, often to describe the mechanical forces of cells or for 
the size-based separation of cells.81-83 To our knowledge, however, no other system 
attempts to describe the interaction of cells and matrices by flowing cells through single 
micron pillar arrays. Likewise, while there are many studies (computational and 
microfluidics-based) that describe aspects of cell deformation, there is not currently a 
system that aptly describes deformation through a physically challenging geometry over 
different time scales, and thus a device to parse out the parameter space for RBC 
deformation versus fragmentation. 30, 35, 84-86 Thus, a simplified system of microcanals was 




Figure 4.1 Schematic of micropillar array and microcanal devices.The micropillar (top) 
and microcanal (bottom) arrays both are highlighted by challenging physical geometries 
that cells are required to transit. The micropillar array is made up of pillars that are 900 nm 
in diameter, 3 µm in height with a 2 µm gap between adjacent pillars. The microcanal array 
features canals of lengths ranging from 5-90 µm with a transit cross-section of 2 µm width 
and 3 µm height  
4.2.2 Device fabrication  
To study the interactions of blood cells with their biophysical microenvironment, 
microfluidic devices were designed to have features on the order of biologically relevant 
matrices, that is < 3 µm. As creating high fidelity features of this dimension using 
traditional photolithography is non-trivial, electron-beam lithography (EBL) was used to 
create a silicon wafer template that could be used to create microfluidics via direct soft 
lithography using the elastomeric polymer, PDMS (Corning). To mitigate the poor silicon 
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to photoresist selectivity for deep etching of the sub-micron features, a layer of SiO2 was 
deposited via plasma-enhanced- vapor-deposition (PECVD) to form a hard mask. Next, a 
thin layer of electron-beam- lithography (EBL) photoresist was spun on the SiO2 layer and 
patterned using the EBL tool. Dry-etching transferred the patterned features from the 
photoresist to the hardmask. The silicon wafer was then etched. While EBL’s sequential 
deep reactive-ion etching (DRIE) and passivation cycles of the Bosch process generally 
result in side wall roughness (scalloping), an optimized recipe, termed the nano-Bosch 
process, results in smooth side walls etched in the silicon substrate. 87, 88 The resulting 
feature smoothness is necessary for the successful release of cured PDMS from the master. 
Thus, using EBL, a silicon master was patterned with holes to create PDMS pillars (~900 
nm diameter and 3 µm height, with a 2 µm gap) or with vias to create PDMS canals (2 µm 
width and 3 µm height, with lengths from 2-90 µm). After patterning, the silicon master 
was vapor treated with HMDS to create a hydrophobic substrate that further encourages 
PDMS release. PDMS (at a 10:1 ratio of elastomer to curing agent) was poured over the 
treated silicon wafer and the wafer was placed in a vacuum chamber for ~1 hour to ensure 
PDMS entry into the micron-sized features. PDMS was then cured overnight at 60 C, 
before the PDMS devices were cut out and the wafer was repoured. The direct EBL-
patterned PDMS “feature layer” serves as the bottom surface of the microfluidic device.  
To create a closed microfluidic device, PDMS channels were created from silicon 
wafers templated via traditional photolithography and SU-8. Surface activation of both 
layers (feature and channel) was accomplished using a handheld Corona Treater (Electro-
Technic Products), and PDMS layers were bonded by aligning them under a microscope 
and placing the bonded device on a hot plate at 80 C for 10 minutes to set bond. The two-
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part system—features on one PDMS layer and channels on another—allows the user to 
mix and match between micron-sized features and channels to study the desired system.  
For platelet micropillar experiments, the channel was 150 µm wide and 6 µm tall, inlet and 
outlet holes were punched ~500 µm from array, and the long axis of the micropillar array 
was bonded perpendicular to flow direction. For RBC and neutrophil micropillar 
experiments, the channel was 150 µm wide and 3 µm high to force the cells through the 
array. The channel for the microcanal device was 26 µm wide and 3 µm tall, and each canal 
was approximately centered between inlet and outlet holes that were ~1 mm apart. An 
additional outlet hole was punched downstream of the first outlet hole to reduce fluidic 
resistance and create a viewing window of cells post-canal. 
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Figure 4.2 Fabrication of single-micron scale devices. (1-3) Electron beam lithography 
(EBL) was used to pattern the silicon wafer. (4) Direct soft lithography was used to transfer 
the pattern from the silicon wafer to PDMS. (5) Release cured PDMS from the silicon mold 
(SEM of PDMS features) and bond the EBL feature layer (A: microcanal, B: micropillar) 
to the desired PDMS channel.  
 
4.2.3 Device characterization  
Inspection and characterization of the PDMS features was achieved by scanning 
electron microscopy (SEM). SEM images confirm that direct lithography from a silicon 
master achieves PDMS pillars and canals of the expected geometries and dimensions 
(Figure 4.2). By performing SEM on devices after a number of pours, we saw that there 
was minimal loss in feature quality after >20 PDMS pours.  
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 Micropillar Array Fluidic Environment 
 
It is well established that blood components respond to shear stress and shear 
gradients, so characterizing the shear microenvironment of the micropillar array is of 
interest.89  Shear stress (τ) in microfluidic channels can be estimated by a 2-D 
approximation as: = , where Q is the flow rate, µ is the viscosity, w is the channel 
width, and h is the channel height. A more precise constant term based on the channel 
dimensions for the shear stress equation with a 3D velocity profile can be found using 
Fourier expansions. 90, 91. Using a two dimensional laminar flow COMSOL model for a 6 
µm tall channel with an input velocity of 0.2 µL/min, the max fluid shear is calculated to 
be ~ 50 dyne/cm2 in the micropillar array. (Figure 4.3) This shear is at the low end of 
pathological shear, or the shear that would be expected in a diseased state. The pillar 
geometry results in areas of high shear as well as stagnant zones behind the pillars; this 
creates areas with large shear microgradients. Different numbers of pillars in the arrays (5 
or 10 columns), and consecutive pillar rows being either offset or inline with one another 
does not change the shear microenvironment. Due to the stiffness of the PDMS pillars 




Figure 4.3. Shear microenvironment in the micropillar array. Shear stress profile in a 6 µm 
tall, 150 µm wide channel with ten columns of aligned micropillars. Close-up of pillar 
environment shows a maximum shear of ~50 dyn/cm2 (shear rate of 5,000 1/s)  
 
 Microcanal fludic environment 
 
The small cross-sectional area of the canals results in a very large shear stress 
(~20,000 dyn/cm2) and while changing the length of the channel changes the length over 
which the cell is exposed to the high shear stress, it does not change the magnitude of the 
shear stress itself. The fluidic resistance in the canals, however, does change with canal 
length, and thus the pressure drop across the canals also changes with canal length. To 
find the pressure differential, I modeled the canal array in 2D with COMSOL, with an 




Figure 4.4 Pressure drop across a 40 µm microcanal device. There is a pressure drop of 
~70 kPa across 40 µm microcanals.  
 
 Pressure calculations in the microcanals can also be approximated by modeling 
microfluidics as circuit.90 Briefly, Ohm’s law, 
 = , (3) 
where V is voltage, I is current, and R is resistance has an analogue in microfluidics via 
the Hagen Poiseuille law 
 = , (4) 
 
where  is the pressure drop across a channel, Q is flow rate, and RH is the hydraulic 
resistance. RH depends on fluid viscosity (µ) and channel width (w), height (h), and 






Pressure drop then varies directly with the length of the microfluidic channel. As in 











The canal fluidic can be treated as a circuit in which there are seven parallel resistors of 
the same resistance, as the channels have the same width, height, and length. The total 





For blood (µ= 3.2x10-3 Pa∙s) perfused at a flow rate of Q=0.5 µL/min, the pressure drop 
across microcanals of w= 2 µm, h =3 µm, and l is: 
 = 4.61 10 ×   [Pa]. (8) 
 
For canal lengths from 10- 90 µm, the pressure drop ranges from ~46 kPa to 415 kPa. We 
also designed microcanals with a cross-sectional area of 3 µm x 3 µm. In this case, the 
pressure drop across the microcanals is: 
 = 1.91 10 ×   [Pa], (9) 
 
resulting in a pressure drop ranging from ~19 kPa to 172 kPa for lengths (l) of 10-90 µm. 
For equivalent canal lengths, the pressure drop across the 2x3 µm cross-section canals is 
~2.4 times that of the 3x3 µm cross-section canals. In other words, a 2x3 µm canal of length 
l has the same pressure drop as a 2x3 canal of length (2.4)∙l. These calculations describe is 
the pressure drop before cells are introduced to the system as confirmed by the Comsol 
model. The pressure environment becomes more dynamic and complicated as cells plug 
individual canals and transit the canals. If a cell is blocking one canal, the pressure in the 
rest of the system increases by a factor of resistance. Thus, if all canals are blocked but 
one, the pressure drop is 7 times those reported above. 
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4.2.4 Introducing Biologics to the PDMS Surface 
Directly after bonding, devices were blocked with 3% BSA via gravity driven flow. 
To ensure fully filled, bubble-free channels, a BSA droplet was pipetted over inlet and 
outlets and devices were placed in vacuum chamber for 1 hour incubation. Other biologics 
were introduced to the PDMS surface by gravity driven flow and passive adsorption: 
fibronectin (10 µg/mL) or collagen (1 mg/mL) incubated for 1 hour.  
4.2.5 Collecting and Staining Human Blood Samples  
Human blood was drawn according to institutional review board–approved protocols 
per the Declaration of Helsinki. Washed platelets were isolated by centrifuging whole 
blood (drawn into ACD) at 150 g for 10 minutes, collecting the supernatant (PRP), and 
centrifuging the supernatant at 900g for 5 minutes. The platelet pellet was then 
resuspended in Tyrode’s Buffer containing 1% BSA. Platelets were stained with 2 uM 
Calcein AM or anti-CD41 antibody (Novus) at 1:200.  RBCs were isolated by 
centrifuging blood (drawn into sodium citrate) at 150g for 10 minutes (no acceleration, 
no brake), discarding the supernatant, and washing 3x with PBS (400g for 7 minutes). 
RBCs were resuspended in PBS to ~20% hematocrit, unless otherwise noted. Staining red 
blood cells with R18 (Sigma) greatly affected their mechanical stability (cells are 
destroyed into membranous debris), and thus all RBC studies were performed using 
bright field microscopy (Figure 4.5). 
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Figure 4.5. R18 stained RBCs fragment into membranous debris when transitting 
microcanals.  When R18 stained red blood cells are perfused through microcanal device, 
cells, they fragment into stringy, membranous cell debris. This suggests that R18 has a 
significant effect on RBC structural integrity.  
 
Neutrophils were isolated from whole blood using MACSxpress® Neutrophil Isolation 
Kit; neutrophils were then washed in PBS (210g for 10 minutes) and resuspended in 
either PBS or PRP. Staining was performed by adding primary and secondary antibody 
directly to the cell mixture.  Neutrophils were stained with a combination of Hoescht 
33342 at 1:000 ; Sytox green at 1:200 ; anti-histone H3 (Abcam, ab5103) at 1:200; or 
anti-elastase (Abcam, ab68672) at 1:200. Samples were perfused through microfluidic 
device at 0.5 µL/min using Harvard Apparatus syringe pump.  
4.3  Results and Discussion 
4.3.1 Platelets Adhere and Aggregate Due to the Physical Presence of Micropillars  
Shear stress is known to be a biophysical activator of platelets, and the pathological 
relevance of shear stress is well described, especially as it relates to von Willebrand 
Factor (vWF) mediated clotting and the progression of atherosclerosis.92-95 Literature 
suggests various shear ranges at which platelets adhere to surfaces, activate in the 
presence or absence of soluble factors, and aggregate.89, 96 In addition, platelets are shown 
to bind immobilized ligands at different shear rates: platelet integrin αIIbβ3 binds 
fibrinogen at low physiological shear rates of 600-900 1/s while platelet integrin GPIb–
A1 binds von Willebrand Factor (vWF) at 1,000-10,000 1/s.97 While many studies 
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specify overall shear stress that platelets encounter, others instead argue that shear 
microgradients are more important to platelet activity.98 Microfluidics allow for the 
piecewise study of these questions, and as our COMSOL simulations show, the 
micropillar array creates regions of high shear as well as stagnant zones.  
The biophysical interaction of platelets with a PDMS matrix (absent biological 
factors) was thus recapitulated by the micropillar microfluidic device. Perfusion of 
washed platelets through the channel results in specific, localized platelet adherence to 
the pillars, extensive platelet aggregation, and the formation of an occlusive mass that 
extends to the edges of the micropillar array to arrest flow. (Figure 4.6)  
 
Figure 4.6. Platelets adhere and aggregate due to physical presence of pillars. Platelets 
(stained with calcein) are perfused at 0.2 µL/min through the micropillar array (white 
outline). The width of the pillar array is 15 µm. 
 
 
Platelet adhesion initiates exclusively at the pillars and aggregation propagates to the 
extents of the channel area perpendicular to flow, resulting in channel occlusion and flow 
cessation. These findings suggest that in the absence of platelet agonists and biological 
ligands, platelets are activated by the shear environment afforded by the physical presence 
of “fibers.” Thus, in addition to the biochemical players in clot formation, the geometry of 
the matrix with which platelets interact plays a role in platelet adhesion and clot 
propagation. As expected, passive adsorption of collagen and fibronectin to the pillar 
surfaces enhances platelet aggregation, as evidenced by a decrease in time to channel 
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occlusion from 10 min to 6 min and 2 min, respectively (Figure 4.7). This finding then 
begins to describe the synergistic action of biophysical and biochemical factors in clot 
propagation. This microfluidic both separates biophysical and biochemical aspects of clot 
formation and allows researchers to specify the precise location and extent of clot 
formation in vitro. Platelets were also perfused through the microcanals, but they did not 
adhere or aggregate within the microfluidic. The gaps are large enough for platelets to 
transit without interacting with the PDMS structures, and while the shear stress is 
sufficiently high for platelet activation, I posit that the lack of stagnant zones (and thus the 
lack of a shear microgradient) throughout the device prevents platelets from activating and 
then adhering. The shear stress in the device is also high enough to discourage adherence.   
 
Figure 4.7. Platelet activity is enhanced by adsorbing biologics to PDMS micropillars The 
average time to channel occlusion (cessation of flow) is graphed for bare pillars, fibrinogen 
coated pillars, and collagen coated pillars. Fibrinogen coated pillars greatly increase 
platelet adherence and aggregate propagation.  
4.3.2 RBC Fragmentation is a Function of Time in Deformed State 
Red blood cells are highly deformable, allowing them to readily transit the 3-4 µm 
diameter capillaries of the microvasculature. They also maintain their oxygen carrying 
capability in the variety of the shear rates experienced in the vasculature. However, it is 
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known that RBCs can fragment in vivo when there is extensive pathological clotting, as 
well as in the presence of heart valve implants. The presence of the resulting cell fragments, 
termed schistocytes, on a blood smear is used as a diagnostic for pathologies such as 
hemolytic uremia syndrome (HUS), thrombotic thrombocytopenic purpura (TTP), and 
disseminated intravascular coagulation (DIC).41, 99 While the in vivo presence of 
schistocytes is documented in the literature and there are many studies about quantification 
methods, the mechanism by which they are formed is not well characterized. A carefully 
conducted SEM study in 1970 reported that schistocytes result when “rapidly moving red 
cells encounter fine fibrin strands,” and the resulting image of “hanged red blood cells” 
from the study is used extensively in medical literature.100 
 
Figure 4.8. Red blood cell wrapped around a fine fibrin strand. SEM of a fixed sample 
from a patient with macroangiopathic hemolytic anemia. This is shown as the visual 
evidence for the mechanism of schistocyte formation. Image taken from [100]  
 
The process of fragmentation is usually described in as a fibrin strand 
instantaneously cutting a cell in two, and the fibrin fibers have even been compared to a 
“guillotine.”101 Damaged RBCs can also rupture, expel their cytoplasmic load—
hemoglobin— and become ghosts, or empty, closed membranous sacks. RBCs have been 
found to hemolyze at fluid-fluid shear interfaces of >15,000 dyn/cm2, and at fluid-solid 
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interfaces between 1,500 and 3,000 dyn/cm2.41 However, the conditions under which these 
disparate states of damage result are largely unknown. Understanding the biophysical 
parameter space for RBC damage, fragmentation, and destruction is of immense interest 
for improved understanding of disease state as well as for development of diagnostics. (See 
Section 2.3.1 for discussion of RBC deformation and morphological abnormalities)  To 
that end, we perfused RBCs in our micropillar and microcanal systems and analyzed their 
deformation in real-time. 
RBCs deform elastically through the micropillar array: RBC morphology changes 
during transit, but RBCs return to their discoid shape upon matrix exit (Figure 4.9). 
 
Figure 4.9. RBCs elastically deform through micropillar array. Over the course of 6 
seconds, RBCs transit array with minimal downstream morphological changes.  
 
 This suggests that forces (including physical constriction) need to be maintained over an 
extended distance to affect plastic deformation of RBCs. To that end, the microcanal 
device challenges RBCs to deform through a 2x3 µm cross-sectional gap over various 
distances (length of canal). At short canal lengths (<20 µm), RBCs elastically deform 
through the canal; however, as canal length increases, RBCs emerge progressively more 
damaged.  At 20-35 µm, a subset of cells emerge from canals as echinocytes—RBCs 
covered in short, blunt spicules—a reversible morphological change that is indicative of 
the ATP loss that is expected when RBCs are exposed to shear deformation (Figure 
4.10).39 At 35 µm lengths, there is intermittent RBC fragmentation, resulting in 
microspherocytes (Figure 4.10, black arrows). 
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Figure 4.10 Time course images show that RBCs traverse short canals with minimal 
damage. As RBCs traverse 10, 35, and 45 µm lengths (top panel to bottom panel), the 
majority of cells emerge with minimal damage. As canal lengths increase, severity of 
damage also increases. Abnormal morphologies are denoted by arrows: blue for burr cells, 
black for microspherocytes, and green for schistocytes. Representative images from N>3. 
 
 
At canal lengths > 70 µm, the majority of RBCs emerge as cell debris and ghosts—
membranous sacs that have expelled their cytoplasmic load, hemoglobin. At interim 
residence times in a deformed state, RBCs emerge in fragmented morphologies: 
microspherocytes, or small spherical RBCs indicative of membrane and/or volume loss, 
and schistocytes. Resulting blood cell morphologies can be described, in part, by Giemsa 
staining of the effluent (Figure 4.13). Taken together these experiments suggest that 
different levels of damage occurs for different canal lengths, and thus possibly based on 
different pressures and times in a deformed state. Quantitatively, we see that the percent of 
damaged cells exiting the canal increases for increasing canal lengths, plateauing at 95% 
Time 
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damage for lengths > 50 µm (Figure 4.12). Based on qualitative analysis, we posit that 
different morphologies emerge at different canal lengths for canals with a 2x3 cross-section 
(Figure 4.14) 
 
Figure 4.11. RBCs emerge damaged after traversing canals of 60, 70, and 80 microns. 
Time lapse of RBCs traversing canals (top to bottom in each column). Abnormal 
morphologies are denoted by arrows: green for schistocytes, blue for burr cells, black for 
microspherocytes, white for ghosts, and red for cell debris. N>3 
 
 
Figure 4.12. RBC damage increases with increasing canal length.  As canal length 
increases, percent of damaged cells increases, beginning at around 30 µm and plateauing 





Figure 4.13. RBC morphologies present in microcanal effluent from a 60 µm canal. It 
appears that passage through canals results in various abnormal RBC. Spherocytes and 
microspherocytes were the most commonly seen abnormal RBC morphologies. Control 




Figure 4.14. Proposed trend between canal length and RBC morphology. Based on 
experimental findings, it seems that ~20-50 µm lengths result in burr cells, >35 µm lengths 
result in spherocytes, >45 µm lengths result in schistocytes, and >70 µm canals result in 
ghosts and cellular debris.  
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If the degree of deformation is reduced by increasing the canal’s cross-sectional 
dimensions to 3x3 µm, RBCs elastically deform for all tested canal lengths (up to 90 µm), 
with no discernible plastic changes (Figure 4.15). An array of 3x3 canals of 90 µm is 
similar in pressure drop to a 2x3 array of canals ~40 µm in length; we thus hypothesize 
that in this system, RBC mechanical damage and fragmentation require both a pressure 
differential and residence time under significant physical constraints. This is supported by 
quantifying the percent damaged cells: even when exposed to pressure drops that cause 
significant damage in 2x3 µm gap devices (40% of cells), all cells passing through the 3x3 
µm array emerge morphologically unchanged (Figure 4.16). 
 
Figure 4.15. RBCs elastically deform through 90 µm canals with 3 µm x 3 µm cross 
section. Time lapse of RBCs traversing 90 µm canals (top to bottom). RBCs emerge with 





Figure 4.16. RBCs emerge from 3x3µm constriction with negligible damage. At the same 
initial pressure drop, 40% RBCs emerge damaged from the 2x3 µm constriction, while 0% 
emerge damaged from the 3x3 µm constriction.  
 
More interestingly, preliminary evidence suggests that pathologically altered RBCs from 
a patient with sickle cell disease (SCD) fragment more readily than RBCs from healthy 
donors. It is known that pathologies introduce mechanical differences that change the 
ability of RBCs to deform through physically challenging matrices, and our finding 
suggest that mechanical changes shift the fragmentation profile. This has implications for 
hemolytic anemias in sickle cell disease. Furthermore, it appears that a subset of cells 
enter the array with a visibly “normal” morphology and emerge an irreversibly sickled 
cells (ISC) (Figure 4.17, white outline.traces ISC).  For instance, at a canal length of 40 
µm, ~40% of health RBCs emerge damaged, while ~90% of SCD RBCs emerge 
damaged (Figure 4.18.  
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Figure 4.17. RBC from a sickle cell disease patient are significantly damaged after 
traversing 40 µm canals.Time lapse of sickle red blood cells emerging from canals shows 
various morphological abnormalities, including spherocytes (black), ghosts (white), and 









Figure 4.18. SCD RBCs fragment more readily than healthy RBCs.  At the same canal 
lengths, RBCs from patients with SCD emerge more damaged than RBCs from healthy 
donors.  
 
This study allows for the real-time visual analysis of RBC deformation and 
fragmentation, but the system is also marked by limitations. Because the processed 
sample volume is on the scale of picoliters, enumeration of cell subtypes from the 
effluent proves difficult. It is also not possible to draw direct correlation between pressure 
differentials and fragmentation profile, for as cells block the canals the pressure drop 
across the other canals changes. The pressure is thus dynamically changing throughout 
the experiments. Tighter control of these variables in future systems would yield more 
direct relationships between fragmentation and biophysical parameters. 
 
4.3.3 Neutrophil Interaction with Microfluidic Matrices Results in Procoagulant NET-
like Morphology  
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Neutrophils are the most numerous WBC subtype, comprising ~60% of the total 
WBC population, and they are well known as the “first responder” of the innate immune 
system as they migrate to sites of infection and phagocytose pathogens. In a process 
termed chemotaxis, neutrophils respond to chemoattractant signals to extravasate from 
the vasculature and respond to infection;  it was recently shown that neutrophils are also 
involved in inflammation resolution via retrotaxis, reverse migration from sources of 
chemokines back to the vasculature.102 Likewise, there is a wealth of recent literature that 
seeks to describe the process and biochemical pathways of NET (nuclear extracellular 
trap) formation, a process in which neutrophils release their nuclear material into the 
extracellular space. 103-106  
NETs are a meshwork of chromatin and DNA studded with histones and cytotoxic 
enzymes, and their release is thought to be part of the neutrophil’s antimicrobial defense 
system, as NET entrapped pathogens are exposed to high concentrations of antimicrobial 
proteins. NETs are released in response to numerous factors, including inflammatory 
stimuli, contact with pathogens, and chemical activation; however, the in vivo 
circumstances in which neutrophils respond by forming NETs instead of phagocytosis is 
not well understood. NETs have been implicated as a complicating factor in numerous 
pathologies, such as sepsis, cystic fibrosis, and rheumatoid arthritis. 106 Furthermore, in 
vivo, NETs have been shown to be procoagulant and to play a role in pathological 
thrombosis.107, 108 A recent in vitro study suggests that intact NETs do not directly 
stimulate coagulation, as measured by thrombin generation, and rather that NET 
components are procoagulant (histones proteins and neutrophil DNA).109 Interestingly, it 
was recently reported that mechanical ventilation in patients with respiratory failure can 
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induce neutrophil extracellular trap formation: ventilation results in NETs, but the 
stimulus is unknown, as bacteria is necessary to recruit neutrophils to the lungs but not to 
create NETs. 110 These recent reports taken together suggest a role for a mechanical 
process in the formation of procoagulant “NET-like” structures. The mechanics of 
neutrophils, as studied through the previously described traditional assays, is well 
established. Mechanical changes during migration and activation have been described, 
and Yap and Kamm suggest that microfluidic constrictions can result in neutrophil 
activation and the formation of pseudopods.111-113 Recently, a computational study 
described the fluidization of the neutrophil as it enters a constriction.114 These studies 
give insight into the mechanical activation of neutrophils and further motivates our 
studies of neutrophil response through single-micron matrices. 
When neutrophils are perfused through the microcanal device, neutrophils fragment 
into stringy, membranous material that adheres to the canals and aggregates under flow 
(Figure 4.19). This is the case for the canals with 5, 10, and 20 µm lengths (and their 
associated pressures) (Figure 4.20). Over time, membranous material from incoming 
neutrophils adds to the material that was left behind by previous passing neutrophils.  
 





Figure 4.20. Time course of neutrophils perfused through microcanals.  Neutrophils 
perfused through 5 µm, 10 µm, and 20 µm microcanals and fragment into membranous  
material that is tethered to the canals. Successive neutrophils add to the membranous 
material left behind from neutrophils that have previously interacted with the canals. 
Accumulation of material is evident when looking down the column for each canal length. 
Scale bar = 20 µm. 
 
We confirm that the material adhered to the canals is indeed from neutrophils by 
staining with the membrane impermeable nucleic acid dye, Sytox green (Figure 4.21). 
Again, membranous material is tethered to the canals and accumulates over time as 
neutrophils are continuously perfused through the device.  The remainder of neutrophil 
experiments were performed in the 20 µm canals as they provide improved scaffolding 
for neutrophil membrane attachment, and thus provide a better platform for the 
characterization of the membranous neutrophil material and its interactions with platelets. 
It is worth noting that the mechanical disruption of neutrophil membranes seen in the 
microcanals also occurs in the micropillar device, but as we are interested in the 
procoagulant nature of neutrophil material, we carried out all experiments in the 




environment in the micropillars. The fragmentation of neutrophils in both devices suggest 
that the required deformation is a more significant factor for formation of neutrophil 




Figure 4.21. Time course of DNA accumulation at canals from fragmented, membranous 
neutrophils.  Membranous neutrophil material represents a “dead” cell as it stained positive 
for membrane impermeable nucleic acid stains (sytox green). Accumulation of material 
can be seen as you move from the top to the bottom panel. White dotted “canals” represent 
location of canals in device. Scale bar = 20 µm.  
 
 To investigate whether the membranous neutrophil material forms a procoagulant 
surface we added isolated neutrophils to PRP at ~1 million cells/ mL and perfused the 
mixture through the 20 µL microcanal device (Figure 4.22). As expected, neutrophils 
(stained for DNA with hoescht) form tethered, membranous material at the microcanals, 




Figure 4.22. Platelets adhere to damaged neutrophil membrane. Platelets and neutrophils 
are perfused through 20 µm microcanals and platelets adhere to the membranous neutrophil 
material—platelets (CD41, green) and neutrophil DNA (hoescht, blue). Top panel: 
brightfield alone, Second: platelets alone, Third: neutrophils alone, Fourth: platelets and 
neutrophils, Fifth: all channels merged. Scale bar is 20 µm.  
 
To further characterize the membranous material that arises from neutrophil’s 
interacting with and transiting the microcanals, and to see whether they might be similar in 
composition to NETs, we added antibodies against histone H3, elastase, and MPO (Figure 
4.23). The membranous structures tethered to the canals are in fact studded with histone, 
elastase, and MPO, all of which are considered to be integral components of NETs. When 
neutrophils in PRP are perfused through microcanals, there is some colocalization between 
platelets and histone, elastase, and MPO. It appears that the greatest colocalization occurs 
between platelets and MPO. Together, this suggests that the NET components implicated 
as prothrombotic are present on the surface of the mechanically induced neutrophil debris. 
This led me to refer to the neutrophil debris as NET-like structures. 
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Figure 4.23. Mechanically induced NET-like material is studded with histone, elastase, 
and MPO, and forms a surface to which platelets adhere. Neutrophil membrane (DNA 
stained with hoescht) that is tethered to the microcanals displays histone, elastase, and 
MPO (red). Images are in pairs, with the top image comprising all channels and the bottom 
shown without brightfield. The left panel is neutrophils perfused on their own and the right 
panel is neutrophils mixed with PRP and perfused through the device. When platelets and 
neutrophils are perfused, the platelets adhere and aggregate on the membranous neutrophil 
material. Some colocalization is seen between platelets and traditional NET components, 
especially in the case of MPO. Scale bar is 20 µm. 
 
NETs have been reported to bind to platelets, RBCs, and proteins and thereby promote 
thrombosis. 104 When RBCs and neutrophils are perfused together through the 
microcanals, RBCs do in fact become trapped in the tethered neutrophil membrane 
(Figure 4.24). RBCs take on a teardrop shape, whereby they are tethered at one end and 
elongate with the flow at the other (Figure 4.25). This suggests that mechanically 
disrupted neutrophils may have a role in RBC fragmentation and destruction. Neutrophils 
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then appear to form procoagulant NET-like structures when they are challenged by 
physical matrices (Figure 4.26). 
 
Figure 4.24. Time course of RBCs tethered in ruptured neutrophil membrane.  RBCs and 
neutrophils are perfused through microcanals. As expected, neutrophils are damaged and 
display NET-like membranous structure as they traverse 20 µm microcanals RBCs interact 





Figure 4.25. RBCs trapped in neutrophil membrane.  Mechanically induced neutrophil 
membranous material traps RBCs as they transit the canals and interact with the neutrophil 
membrane. RBCs are teadrop shaped as they appear to elongate with flow while their 
membrane is tethered to the neutrophil membrane material.   
 
Figure 4.26. Platelets and RBCs interact with mechanically- induced NETs-like substrate  
Schematic shows the posited interaction of blood cells with a vascular matrix. As a 
neutrophil enters the matrix, it collides with fibers and fragments. The resulting NET-like 




4.4  Conclusions  
 In this chapter we were able to leverage fabrication technologies to create a suite 
of microfluidic devices that allow for the real-time monitoring of blood cell transit 
through matrices whose dimensions are on the single micron scale. In doing so, we are 
able to recapitulate the passage of blood cells through physical challenges that are on the 
size scale of biological matrices, while still being able to decouple the effects of the 
physical presence of a matrix from the biological components of the matrix. Overall, we 
show that mechanical forces alone have significant, and sometimes surprising, effects on 
blood cells. We find that when platelets are perfused through a micropillar array (pillars 
are 900 nm in diameter, 3 µm in height, and there is a 2 µm gap between pillars), in the 
absence of agonists or biological ligands, platelets adhere in the array, aggregate, and the 
mass extends to the edges of the array until the channel is fully occluded. I posit that this 
spatially localized response to the physical presence of pillars is due to the shear 
microgradients created by the pillars and the stagnant zones throughout the array. 
Occlusion of the microchannel can be hastened by taking advantage of the synergy 
between the biophysical and the biochemical by adsorbing platelet ligands to the 
micropillars.   
 While it is known in vivo that RBCs fragment in response to mechanical forces, 
the mechanism of action of RBC fragmentation is not well understood. Although it was 
hypothesized that the extent of deformation required for RBCs to pass through the 
micropillar array would lead to RBC fragmentation, we found that RBCs were able to 
transit the pillar array without undergoing plastic deformation. This led us to consider the 
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temporal aspect of membrane remodeling that might result in fragmentation versus 
outright destruction of RBCs. To that end, we created a microfluidic device that features 
an array of canals to probe the deformation of cells as a function of time in deformed 
state. We found that over long periods of deformation (as controlled by the length of the 
canals) we could induce RBC fragmentation and watch fragmented cells exit the canals in 
real time. The extent of RBC damage, and thus the resulting morphological abnormality 
was dependent on the length of the canal (which corresponds both to residence time in 
deformed state and pressure differential). We were able to see mild, reversible damage in 
the form of echinocytes at short canal length, microspherocytes and schistocytes at 
intermediate lengths, and RBC ghosts and cell debris at the longest canal lengths. 
Preliminary findings suggest that pathologically abnormal cells (from a patient with 
SCD) show a different fragmentation profile than do healthy cells, and that extreme 
deformation may even induce irreversible sickling.  
Finally, although NETs are thought to be created in response to biochemical 
stimuli provided by a pathogen or an inflammatory response, we show that by perfusing 
neutrophils through our microcanal device, we can create “NET-like” membranous 
structures that are marked by DNA, histone, elastase and MPO. Moreover, this 
mechanically damaged neutrophil membrane appears to be procoagulant: platelets adhere 
to the membranous substrate and colocalize with histone, elastase, and MPO. The recent 
report that NET components, as opposed to intact NETs, are procoagulant combined with 
our findings herein suggest that a purely mechanical stimulus could be implicated in the 
prothrombotic role of neutrophils.  This neutrophil debris is further able to trap RBCs, at 
which point their membranes undergo deformation that can possibly lead to RBC ghosts 
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and fragmentation. In all, these findings suggest that there is an exquisite synergy 
between sepsis, microangiopathies, and hemolytic anemias that has roots in the three 
major cells present in blood, that may be at least in part mechanically regulated. 




CHAPTER 5: CONCLUDING REMARKS AND FUTURE 
DIRECTIONS 
Microfluidics provide a platform to study hematology in a reductionist manner that 
uniquely allows for the study of the independence and the interaction of the biophysical 
and biochemical aspects of hematology. My work shows that microfluidics can supplement 
in vivo studies, provide mechanistic insights into in vivo processes, and answer biophysical 
questions that were previously not technically feasible to answer. The long-term goal of 
this work is to determine how biophysical factors contribute to hematological processes, 
and thereby expand solution spheres for novel therapeutic targets and innovative 
diagnostics assays.  
 In the first part of my work, I was able to leverage microfluidics to resolve the 
mechanism of action of the most commonly used injury model for studying thrombosis—
the FeCl3-induced thrombosis model. My work with the FeCl3 injury model shows the 
value of companion in vitro systems in determining the mechanisms of action of biological 
processes and in resolving discrepancies between findings in the literature. It also suggests 
ways in which in vitro systems could be used to supplement, or in some cases, replace 
animal-based injury models. I found that the initiating events in clotting in this injury model 
are non-biological in nature, and that researchers should use caution in interpreting their 
results if they choose to continue to use this model. Thus, my findings both inform future 
hematological research and serve to reconcile literature findings. While overall, this project 
serves as a closed chapter, it further suggests that biophysical factors, such as the role of 
mass transfer, should not be overlooked in biological assays.  
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 The suite of devices that I created to probe the biophysical interactions of cells with 
physical challenges have provided exciting initial insights into blood cell/ matrix 
interactions, but these studies have served to inspire more questions about these processes. 
Our work shows that the physical presence of a matrix can lead to platelet adherence and 
aggregation. This provides insight into the fluidic environments that induce platelet 
activation and aggregation, and allows researchers to specify the location of a clot in their 
system. Elucidating the roles that additional matrix proteins play in this aggregation and in 
the propagation of the thrombus would enhance our findings. 
Using the microcanal device we were able to show, for the first time, the real-time 
fragmentation of RBCs. The time dependency of fragmentation (or schistocyte formation) 
suggest that fragmentation is not an instantaneous process due to the application of a force, 
as it is often described in medical literature. Furthermore, our preliminary data from patient 
blood shows that sickle cell red blood cells show a much different fragmentation profile 
than does healthy blood. Moreover, cells emerged from the canals irreversibly sickled. 
These studies then begin to provide insight into the biophysical parameter space that results 
in schistocyte formation, but there are certainly limitations in our experiments: namely, 
that pressure is not tightly controlled in our system and thus the pressure that cells are 
exposed to changes dynamically as canals are blocked by transiting cells. Further studies 
should aim to create a pressure controlled system and/or a system in which pressure and 
residence time in a deformed state can be considered separately. Moreover, schistocytes 
are said to form in vivo when red blood cells interact with fine fibrin strands. Creating a 
device using technology, such as the new Nanoscribe 3D printer, with which a repeatable, 
biophysical, nanoscale matrix could be created to view these more physiologically similar 
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interactions would provide additional insights. Likewise, integration of a viewing window 
where different RBC morphologies could be more accurately enumerated, would provide 
additional information. 
Our suite of microdevices also suggests for the first time that the biophysical 
presence of a matrix can mechanically disrupt neutrophils and create NET-like structures 
whose surface is procoagulant and studded with MPO, elastase, and histone.  Further 
studies into these mechanically-induced “NETs” could provide a clear link between 
inflammation and thrombosis. Not only do platelets adhere to the neutrophil membranous 
material, but RBCs are trapped within the fibrous strands and are seen to be in a deformed 
state. Neutrophils could therefore be playing a significant role in schistocyte formation and 
hemolytic anemias.  It is further posited that the stiffness changes resulting from the 
exposure of neutrophils to inflammatory stimuli, would predispose neutrophils to 
mechanically-induced fragmentation. This would further support a synergistic relationship 
in sepsis, NET formation, microangiopathies, and hemolytic anemias. Our work therefore 
begins to explore new areas of research that are based on biophysical interactions. 
Considering alternative therapeutic targets that stem from newly discovered biophysical 
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